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 The purpose of this study was to examine the effects of lifestyle activity 
modification (LAM) and structured exercise on the non-traditional cardiovascular risk 
factors C-reactive protein (CRP) and plasminogen activator inhibitor-1 (PAI-1), in 
sedentary, African American Women.   Subjects were randomized to a control group, a 
structured exercise group, or LAM group for a twelve week intervention. 
 A repeated measures ANOVA showed that both the exercise and LAM group 
significantly improved their predicted VO2max and daily physical activity level.  The 
exercise group significantly decreased their percent body fat and the control group 
significantly increased their waist circumference, while there were no changes in the 
LAM group.  There were no changes in insulin, glucose, CPR or PAI-1. 
 Results show that both LAM and structured exercise improved cardiovascular 
fitness and prevented an increase in waist circumference in this cohort, but neither 
improved levels of CRP or PAI-1. 
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CHAPTER I 
INTRODUCTION 
 
 
Background 
 Atherosclerosis is a disease of the arteries and is the primary cause of heart 
disease and stroke.  It is a progressive disease in which lipids and fibrous debris 
accumulate in the arteries, often leading to thrombotic event(s) (Lusis, 2000).  Metabolic 
syndrome, insulin resistance and type 2 diabetes are all metabolic disorders, often 
associated with atherosclerosis. Metabolic syndrome is a cluster of abnormalities 
including obesity, dyslipidemia, hyperglycemia, and high blood pressure (NCEP Panel 
III, 2001). When insulin resistance is present, insulin-mediated glucose uptake does not 
respond properly to changes in insulin (Vague and Raccah, 1992) which leads to 
hyperglycemia, a hallmark of dysfunction in glucose homeostasis.  Obesity is a major 
component and contributor to both atherosclerosis and metabolic disorders and both are 
highly correlated with incidence of type 2 diabetes (Tkac, 2005, Vague and Raccah 
1992).   African-American women have higher rates of obesity and type 2 diabetes, 
making them a high risk group for the development of atherosclerosis and/or metabolic 
syndrome (Mokdad et al, 2003, Ogden et al, 2006). 
 Recently, it has been proposed that both atherosclerosis and metabolic disorders 
are related to inflammation (Manuel et al, 2003, Ross, 1999, Yeh, 2004).  C-reactive
 1
 
protein (CRP) and plasminogen activator inhibitor-1 (PAI-1) are two non-traditional 
cardiovascular risk markers that may be used to identify the possible risk of developing 
insulin resistance, type 2 diabetes, metabolic syndrome and/or atherosclerosis in the 
future.  CRP is an acute phase reactant produced in response to infection and 
inflammation (Black et al, 2004, Du Clos, 2000, Munford, 2001).  Elevated levels of 
CRP are associated with hypertension, obesity, diabetes, and dyslipidemia (Pearson et al, 
2003). CRP is also directly associated with production of reactive oxygen species, 
platelet adhesion and aggregation, and production of adhesion molecules, all of which 
leads to endothelial dysfunction and an increased risk of developing atherosclerosis 
(Pasceri et al, 2000, Russo et al, 2002). 
PAI-1 is the main regulator of plasminogen activation and the fibrinolytic system.  
The fibrinolytic system is responsible for disrupting blood coagulation, thus preventing 
the removal of intravascular thrombi.  Elevated levels of PAI-1 disrupts this natural 
process, decreasing the degradation of extracellular matrix and increasing the risk of 
experiencing a cardiovascular event (Juhan-Vague et al, 1999, Mavri et al, 2004, Speiser 
et al, 1988). 
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Chronic Inflammation 
expressed by  
↑Nontraditional 
Cardiovascular Risk 
Factors   
(PAI-1 and CRP) 
Insulin 
Resistance 
Endothelial 
Dysfunction 
Glucose Intolerance and 
↑ Insulin 
Atherosclerosis and/or 
Metabolic Syndrome  
 It has been proposed that lifestyle modification of physical activity may prevent 
and/or reverse the development of atherosclerosis and metabolic disorders.  The Centers 
for Disease Control and the American College of Sports Medicine now recommend that 
adults accumulate 30 minutes of moderate-intensity physical activity each day to improve 
cardiovascular health (Pate et al, 1995, US Department of Health and Human Services, 
1996).  It is important to investigate whether or not these new activity guidelines will 
alter levels of non-traditional cardiovascular risk factors in African-American women. 
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Statement of Problem 
 Regular structured physical activity has been shown to improve cardiovascular 
health and reduce the co-morbidities associated with obesity.  Few research studies have 
been done to see if short exercise bouts done two-three times per day will yield the same 
benefits as long, continuous bouts, specifically for cardiovascular risk factors (Hardman, 
2001).  Recently, non-traditional cardiovascular risk factors have been examined in an 
attempt to identify new ways to track cardiovascular disease (CVD).  The purpose of this 
investigation is to examine the effects of lifestyle activity modification (LAM) versus 
traditional structured exercise, compare to controls, on non-traditional cardiovascular risk 
factors in African-American (AA) women.   
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Specific Aim 1: 
To determine the effects of 12 weeks of LAM and traditional exercise on non-traditional 
cardiovascular risk factors CRP and PAI-1 in previously sedentary, African-American 
women. 
Hypothesis 1: Both LAM and traditional exercise will decrease fasting levels of 
CRP and PAI-1 in previously sedentary, African-American women in comparison 
to controls. 
Rationale: The magnitude of the improvement in CRP and PAI-1 is often 
associated with the level of energy expenditure and/or amount of fat loss and 
decrease in BMI. Since both LAM and traditional exercise have been shown to 
increase energy expenditure, decrease percent body fat, and improve 
cardiovascular health in a similar fashion, CRP and PAI-1 are expected to 
decrease in both groups. 
Specific Aim 2: 
To compare the differences in the magnitude of the effect of LAM and traditional 
exercise on non-traditional cardiovascular risk factors CRP and PAI-1 in previously 
sedentary, African-American women. 
Hypothesis 2: LAM and traditional exercise will be equally effective at lowering 
levels of CRP and PAI-1 in previously, sedentary, African-American women in 
comparison to controls. 
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Rationale:  There has been no research comparing alterations in CRP and PAI-1 
in LAM and traditional exercise groups.  Both CRP and PAI-1 levels tend to 
decrease with a decrease in BMI and/or fat mass.  Assuming energy expenditure 
and the resultant decreases in BMI and/or fat mass are similar in both groups, 
CRP and PAI-1 levels should decrease equally in both groups. 
Specific Aim 3: 
To compare the relationship between changes in body composition and changes in the 
non-traditional cardiovascular risk factors, CRP and PAI-1. 
Hypothesis 3: Alterations in both CRP and PAI-1 will be positively correlated to 
changes in body composition. 
Rationale: Since, both CRP and PAI-1 are closely related to BMI, percent body 
fat and fat mass, individuals with largest decrease in BMI or fat mass will show 
the largest decrease in CRP and PAI-1.   
 
SUMMARY 
 This study will investigate the extent to which lifestyle activity modification and 
structured exercise effects PAI-1 and CRP, non-traditional risk-factors for cardiovascular 
disease.  It will further investigate the difference in effect, if any, that the two different 
activity modes have on PAI-1 and CRP.  More importantly, these risk factors will be 
examined in a high-risk population, African-American women, for which little research 
has been done. 
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CHAPTER II 
REVIEW OF LITERATURE 
 
 
 
 This review of literature will discuss atherosclerosis and metabolic disorders as  
 
diseases of inflammation.  Both C-reactive protein (CRP) and plasminogen activator 
inhibitor-1 (PAI-1) are non-traditional cardiovascular risk factors that may be used to 
identify individuals at risk for future development of atherosclerosis and/or metabolic 
disorders.  CRP and PAI-1 and their association with atherosclerosis, metabolic disorders, 
and obesity will be discussed.  More specifically, CRP and PAI-1 in African-American 
women will be examined and the effects of exercise on CRP and PAI-1 will be explored. 
 
Atherosclerosis 
Atherosclerosis is a progressive disease in which lipids and fibrous debris 
accumulate in the arteries and it is the primary cause of heart disease and stroke (Lusis, 
2000).  Recently, research has suggested atherosclerosis may be a disease of 
inflammation, which develops in response to endothelial damage and/or injury.  The 
inflammation hypothesis of atherosclerosis states that local inflammatory stimuli change 
the milieu of the arterial wall and prompt production of adhesion molecules and 
chemokines (Ross, 1999, Yeh, 2004). In a healthy, basal condition, the endothelium 
forms a barrier between elements in the blood and the vessel wall.  An antithrombotic 
surface is maintained through secretion of vasoactive substances and the endothelium 
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modulates inflammatory responses, regulates vessel tone (via nitric oxide), and prohibits 
proliferation of the vascular smooth muscle cells (Russo et al, 2002).    However, with 
chronic endothelial damage leading to inflammation, endothelial dysfunction may 
occur resulting in arterial lesions and ultimately the development of atherosclerosis 
(Libby and Ridker, 2004, Ross 1999, Yeh, 2004).   
The initial insult to the arterial wall is often accompanied by the accumulation of 
oxidized low-density lipoproteins (LDL) and causes an alteration of normal homeostatic 
properties resulting in increased adhesiveness due to the up-regulation of adhesion 
molecules such as vascular adhesion molecule-1 (VCAM-1) and intercellular adhesion 
molecule-1 (ICAM-1) (Lusis, 2000, Ross, 1999).  VCAM-1 and ICAM-1 receptors cause 
leukocytes in the blood to adhere to the vascular endothelium.  Eventually these 
monocytes migrate into the intima and become intimial macrophages, a process that is 
promoted by monocyte chemoattractant protein-1 (MCP-1).  The process of lesion 
formation, endothelial permeability, up-regulation of adhesion molecules, and migration 
of leukocytes into the artery wall are all part of endothelial dysfunction (Libby and 
Ridker, 2004, Ross, 1999). 
Once inside the arterial wall, these intimial macrophages then express scavenger 
receptors which engulf lipoproteins and become foam cells.  These pro-inflammatory 
foam cells become apoptotic, which leads to the production of a necrotic lipid core.  
Smooth muscle cells are then recruited from the media to help in the repair process and 
form a fibrous protective cap over the necrotic material.  This remodeling process leads 
to an enlarged lesion, which leads to chronic dilation in an attempt to compensate for the 
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lesion.  Eventually, the artery can no longer compensate and the lesion will invade the 
lumen, impeding blood flow and possibly resulting in a rupture which ultimately leads to 
a vascular event (Libby and Ridker, 2004, Munford, 2001, Ross 1999, Yeh, 2004).  
 
Metabolic Disorders 
Insulin resistance is defined as resistance to insulin-mediated glucose uptake, 
which is often accompanied by a compensatory increase in insulin levels (i.e. 
hyperinsulinemia).  Insulin resistance is usually secondary to excessive body weight, 
especially visceral fat accumulation in the abdominal area.  As visceral fat becomes less 
sensitive to insulin, lipolytic action is altered and visceral fat releases a large flux of free 
fatty acids into circulation.  This increases hepatic gluconeogensis and lipoprotein 
synthesis and diminishes hepatic insulin clearance.  This process leads to hepatic and 
muscle resistance to insulin-mediated glucose uptake and excess synthesis of 
triglycerides (Vague and Raccah, 1992).  This insulin resistance is often present with 
metabolic syndrome.  Metabolic syndrome is defined (according to the National 
Cholesterol Education Program-ATP III) as having three or more of the following 
criteria: abdominal obesity (waist >88 cm in females and >102 cm in males), low HDL 
(<50 mg/dl), elevated triglycerides ( ≥150 mg/dl), elevated glucose (≥110 mg/dl), and 
high blood pressure (≥130/85 mm Hg) (NCEP Panel III, 2001). 
Insulin resistance and the metabolic syndrome tend to induce a prothrombotic 
state.  Interleukin-6 (IL-6), tumor necrosis factor (TNF), PAI-1 and CRP are all elevated 
with the metabolic syndrome which suggests that inflammation may trigger insulin 
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resistance (Juhan-Vague et al, 2002). Metabolic syndrome and insulin resistance may 
further promote atherosclerosis by the formation of advanced glycosylation endpoints 
(AGEs) which interact with endothelial receptors.  AGEs increase endothelial 
permeability, leukocyte adhesion and decrease nitric oxide production (Lusis, 2000). 
Given this, many metabolic conditions, such as insulin resistance, metabolic syndrome 
and type 2 diabetes, have recently been considered diseases of inflammation (Manuel et 
al, 2003).   
Obesity is a major contributor to metabolic syndrome, more specifically visceral 
obesity (Juhan-Vague et al, 2002).  From 1988-1994, the prevalence of metabolic 
syndrome in United States adults was 23.1%.  This number increased to 26.7% in 1999-
2000.  Concomitantly, the percentage of adults with abdominal obesity went from 38.3% 
to 44%, which may contribute to the increase in metabolic syndrome (Ford et al, 2004).  
The 2001 Behavioral Risk Factor Surveillance System revealed that 58% of the 
population is overweight (BMI ≥ 25 kg/m2) and 20.9% are obese (BMI ≥ 30 kg/m2).  
Furthermore, 7.9% of the population has diabetes.  When this is broken down by ethnic 
groups, 31.1% of the African-American population is obese and 11.2% have diabetes 
(Mokdad et al, 2003). 
In 2003-2004, 66.3% of adults were defined as either overweight or obese and 
32.2% were obese.  The prevalence of obesity was higher in women (33.2%) than men 
(31.1%) and was significantly different across ethnic groups, with non-Hispanic 
Caucasian women at 30.2% and non-Hispanic black women at 53.9% (Ogden et al, 
2006). 
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African-American Women 
More specifically, the National Health and Nutrition Examination Survey for 
2003-2004 reported that 81.6 % of African-American women are classified as overweight 
or obese and 53.9% are obese (Ogden et al, 2006).  Additionally, African-American 
women have the highest percentage of diabetes (11.2%) compared to any other ethnic 
group (Mokdad et al, 2003). Generally, obesity is associated with increased risk of 
cardiovascular disease (CVD); however studies with African American women are 
controversial.  Some studies show that in Africa-American women, body weight and/or 
body mass index (BMI) are not associated with higher rates of CVD (Calle et al, 1999, 
Schmidt et al, 1996, Stevens et al, 1998) while others have found a link between obesity 
and CVD morbidity (Adams-Campbell et al, 1995, Folsom et al 1998). 
 Data from the North Carolina Well Integrated Screening and Evaluation for 
Women Across the Nation (Nelson et al, 2002) showed that in a population of low 
income, middle-aged women, the prevalence of obesity was greater in African-
Americans.  In their sample, only 13% had a normal BMI, 28% were classified 
overweight, and 59% were considered obese.  In comparison, the values for Caucasian 
women 31%, 34%, and 35%, respectively. Appel et al (2002) found that in a sample of 
1110 women, African-American women had a significantly higher BMI (29.5 kg/m2) and 
weight (78.5 kg) than Caucasian women (25.5 kg/m2 and 69 kg, respectively).  In 
addition, African-American women reported a higher incidence of CVD and diabetes.  
Appel et al (2002) argued that the differences observed between ethnicity and these 
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variables may be a function of socioeconomic status, as opposed to ethnicity itself.  
However, Winkleby et al, (1998) showed that the increased prevalence of obesity 
observed in African-American women compared to Caucasian women occurred at all 
socioeconomic levels and Sharma et al (2004) showed a higher rate of CVD risk factors 
in African-Americans compared to Caucasians regardless of education. 
 Mathews et al (2005) examined ethnic differences in cardiovascular risk factors in 
women. Results showed that 48.9% of African-American women were obese compared 
to 28.9% of Caucasian women.  In addition, African-American women had higher CRP 
and PAI-1 levels.  However, once adjusted for education, physical activity, total calories 
consumed and amount of calories from fat, PAI-1 levels were no longer significantly 
higher and CRP differences decreased, but still remained significant. 
 The National Heart, Lung and Blood Institute Growth and Health Study followed 
young girls over the course of 10 years to assess early childhood obesity and fat 
distribution as a predictor of the development of metabolic syndrome. At baseline (8-9 
years of age), African-American girls had significantly higher BMI, waist circumference, 
insulin, glucose and HOMA-IR values compared to Caucasian girls.  Ten years later, 
these differences remained significant.  The average BMI for African-American girls was 
27.5 kg/m2 compared to 19.3 kg/m2 for the Caucasian girls. With increasing age, the 
insulin and glucose levels decreased in both groups, but Caucasian girls had a greater 
decrease and the absolute value of HOMA-IR remained lower. The prevalence of 
metabolic syndrome at ages 18-19 was 3.6% in African-American and 3.0% in Caucasian 
girls (Morrison et al, 2006). 
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 In a study comparing the differences in obesity and diabetes in different ethnic 
groups, African-American women had significantly higher BMI, waist girth, 
subcutaneous and truncal fat, [measured via dual-energy x-ray absorptiometry (DEXA)], 
compared to Caucasians.  However, visceral adipose tissue, measured via computed 
tomography (CT), did not differ between Caucasian and African-American women. Age-
adjusted prevalence of type 2 diabetes was 5.8% among Caucasians and 12.1% among 
African-Americans. Interestingly, type 2 diabetes prevalence increased with increasing 
levels of visceral adipose tissue in Caucasian women, but not in African-American 
women (Araneta and Barrett-Connor, 2005).  These studies show that African-American 
women tend to have a higher prevalence of obesity, CVD, and diabetes than Caucasians. 
 
C-Reactive Protein (CRP) 
 Proinflammatory risk factors that may contribute to the pathophysiology of 
atherosclerosis include elevated levels of oxidized LDL, proinflammatory cytokines such 
as interleukin-1 (IL-1) and TNFα, inflammatory stimuli such as IL-6, ICAM-1, VCAM-1 
and selectins and acute-phase reactants such as CRP (Pearson et al, 2003).  
Acute phase reactants or proteins bind to the surface of invading microbes and 
mark them for destruction by phagocytes and the complement system.  They can also 
serve as anti-inflammatory agents, neutralizing proteases, oxidants, and pro-inflammatory 
cytokines.  Additionally, acute phase reactants can promote the use of endogenous 
nutrients by activating lipolysis, gluconeogenesis, and glycogenolysis when necessary.  
Lastly, they can serve as procoagulants.  Although these proteins provide an important 
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survival function, repeated activation of this system for prolonged periods can be harmful 
(Munford, 2001). 
CRP is an acute phase reactant which is produced by the liver in response to 
infection, inflammation, and trauma.  Clinically, CRP is used to monitor the 
inflammatory response.  CRP can also function as an opsonin and can activate the 
complement system, which plays a role in host defense mechanisms and in the 
inflammatory response. CRP’s influence on the complement system shows that CRP has 
an ability to protect the organism from infection. To date, no deficiencies in CRP have 
been found, suggesting that CRP is a crucial in vivo protein (Black et al, 2004, Du Clos, 
2000, Munford, 2001). 
Production of CRP by hepatocytes is regulated at the transcriptional level by IL-6 
and can be enhanced by interleukin-1β (IL-1β) (Moshage et al, 1988).  Specifically, 
C/enhancer binding protein family members are critical for induction of the CRP gene.  
CRP increases release of interleukin-10 (IL-10),  represses synthesis of interferon-γ, 
stimulates interleukin-8 (IL-8) release, increases PAI-1 levels and activity, and increases 
the release of IL-1β, IL-6, and TNF-α (Black et al, 2004, Ballou and Lozanski, 1992). 
Set levels for CRP, as a relative risk, in a clinical setting are: <1mg/L (low), 1-3 
mg/L (moderate), >3mg/L (high).  These risk cut-offs are based on samples from >15 
different populations and > 40,000 samples (Pearson et al, 2003).   It has been found that 
the high category has a 2-fold increase in relative risk for CVD compared to the low 
category.  In general, elevated levels of CRP are seen with elevated blood pressure, high 
BMI, smoking, metabolic syndrome and/or diabetes, low HDL, high triglycerides, 
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hormone replacement therapy, chronic infection and chronic inflammation.  Decreased 
levels of CRP are seen with moderate alcohol consumption, increased physical activity, 
weight loss, and certain medication such as statins, fibrates, and niacin (Pearson et al, 
2003). 
CRP and atherosclerosis 
There are several mechanisms by which CRP may be involved in atherosclerosis.  
When CRP is introduced into human aortic endothelial cells, there is a dose-dependent 
inhibition of endothelial nitric oxide synthase (eNOS) mRNA levels and a decrease in 
eNOS bioactivity (Venugopal et al, 2002).  Lower eNOS activity reduces the synthesis of 
nitric oxide (NO).  Decreased production of NO increases vascular oxidant stress via the 
production of reactive oxygen species (ROS) and promotes platelet adhesion and 
aggregation.  In addition, decreased NO and the presence of ROS together stimulate 
vascular smooth muscle cell proliferation and migration into the intima leading to the 
production of extracellular matrix.  These processes together exacerbate endothelial 
dysfunction which leads to atherosclerosis (Russo et al, 2002).   
High levels of CRP can also induce the expression of adhesion molecules VCAM-
1 and ICAM-1 by endothelial cells.  Specifically, elevated levels of these adhesion 
molecules were seen at CRP levels of 5 mg/L and were maximal at 50 mg/L (Pasceri et 
al, 2000).  Furthermore, CRP induces monocyte chemoattractant chemokine-1 synthesis 
which promotes leukocyte migration through arterial endothelium (Pasceri et al, 2001), 
and increases proliferation and migration of vascular smooth muscle cells and increases 
ROS production, all of which play a role in endothelial dysfunction and the development 
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of foam cells (Wang et al, 2003).   These results indicate that CRP may not only be a 
marker of inflammation and atherosclerosis, but may actually promote the development 
of atherosclerosis.  
Research indicates that CRP levels in the high-normal range (>3 mg/L) are a 
prognostic marker for future vascular events (Ridker et al, 1998, Ridker, 2001, Ridker et 
al, 2002).  In male subjects followed over several years, those who were in the highest 
quartile range (≥ 2.11 mg/L) of baseline CRP had three times the risk of future 
myocardial infarction (MI) compared to those in the lowest quartile (Ridker et al, 1997).  
Ridker et al (1998) specifically looked at women and found that those who eventually 
developed cardiovascular events (over 3 years), had higher baseline CRP measures than 
their age and smoking matched controls.  
In the Women’s Health Study, investigators examined healthy postmenopausal 
women and compared CRP levels among those that had subsequent cardiovascular (CV) 
events to those who did not.  In general, individuals with CV events had higher body 
weights at baseline and were more likely to have hypertension, diabetes, and/or parental 
history of early myocardial infarction.  Baseline levels of CRP were significantly higher 
in women who subsequently had a CV event compared to those who did not.  When 
compared to other inflammatory or lipid markers, CRP levels were the most powerful 
predictor of CV risk (Ridker et al, 2000). 
 Likewise, Ridker et al (2002) examined CRP and LDL cholesterol in women (45 
years and older) over an eight year period, in order to establish the timing of the first CV 
event.  A CV event was defined as nonfatal myocardial infarction, nonfatal ischemic 
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stroke, coronary revascularization procedures, and death from CV causes.  Results 
showed that CRP was a stronger predictor of future CV events than LDL cholesterol.  
This prediction still held when analysis was adjusted for smoking, age, diabetes, blood 
pressure, and use of hormone-replacement therapy.  Those with both high CRP and LDL 
cholesterol had the highest occurrence of a CV event. 
CRP and metabolic disorders 
In addition to playing a role in the development of CVD, inflammation may also 
play a role in the development of insulin resistance, metabolic syndrome and/or type 2 
diabetes.  In order to investigate this possibility, subjects from the Women’s Health Study 
were screened to investigate whether or not an association existed between inflammation 
and later development of type 2 diabetes.  At a four-year follow up, 188 confirmed cases 
of type 2 diabetes were identified (excluding those who developed type 2 diabetes within 
one year of baseline measures) and 362 matched controls were included.  Anyone who 
developed type 2 diabetes within one year of baseline measures, had a HbA1c greater 
than 6.5%, or had a history of hypertension, hyperlipidemia, or used hormone 
replacement therapy were excluded (Pradhan et al, 2001).   
At baseline, BMI, CRP, fasting insulin and HbA1c levels were significantly 
higher in those who subsequently developed diabetes compared to controls.  In addition, 
those who later developed diabetes had a significantly lower frequency of exercise 
compared to controls at baseline.  When baseline measures of CRP were broken into 
quartiles, the relative risk for increasing quartiles of CRP were, 1.0, 2.2, 8.7 and 15.7, 
respectively (p < 0.001) (Pradhan et al, 2001). 
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Since there was a significant correlation between BMI and CRP, BMI was 
divided and stratified into tertiles of low, medium and high and then the relative risk of 
incidence of diabetes was determined.  Results indicated that higher levels of baseline 
CRP were associated with an increased risk of developing type 2 diabetes regardless of 
BMI.  Even in women with a lower BMI (< 29 kg/m2), there was an augmented stepwise 
elevation in risk with increased levels of CRP.  Even after a fully adjusted model 
including BMI, family history, smoking, alcohol consumption, physical activity, and 
hormone replacement therapy, CRP remained a significant predictor of later development 
of type 2 diabetes (Pradhan et al, 2001).  This association between CRP levels and type 2 
diabetes is strengthened by Figaro et al (2006) who found that elderly patients with type 
2 diabetes had significantly higher CRP values than those who did not.  Additionally, 
Oberbach et al (2006), found that the mean CRP level in patients with type 2 diabetes, 
impaired glucose tolerance, and normal glucose tolerance was 7.5, 3.0, and 2.0 mg/L, 
respectively.  
However, studies examining metabolic syndrome and CRP have not found similar 
results.  Lamonte et al (2005) investigated the association between fitness, CRP and 
metabolic syndrome in a racially diverse sample of women.  Metabolic syndrome was 
defined according to the National Cholesterol Education Program-ATP III criteria.  For 
all women, the prevalence of metabolic syndrome, elevated CRP (> 2.0 mg/L), and 
combined metabolic syndrome and elevated CRP was 22.6%, 45.9%, and 17.8% 
respectively.  Metabolic syndrome was significantly correlated with CRP levels.  
However, adjustment for fitness level (determined by maximal treadmill exercise test) 
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attenuated the association between metabolic syndrome and CRP.  In addition, after 
adjusting for age and race, women with high CRP and metabolic syndrome were more 
likely to have an elevated Framingham score for coronary heart disease (CHD) risk than 
those without either risk factor.  Again this association was eliminated when adjusting for 
maximal METs achieved on the treadmill test.   
These results suggest that the association between CRP and metabolic syndrome 
is eliminated when fitness level is considered (Lamonte et al, 2005).  However, it must be 
noted that BMI was controlled for in all analyses and BMI and fitness level are closely 
related.  Controlling for BMI may explain why there was an association between 
parameters of metabolic syndrome and CRP and the lack of association between CRP and 
fitness level. Overall these data suggests that CRP may be an independent predictor for 
future development of diabetes or the metabolic syndrome and fitness level may attenuate 
this prediction. 
CRP and obesity 
Research indicates a significant correlation between obesity and CRP.  Tchernof 
et al (2002) evaluated CRP levels in a group of obese Caucasian postmenopausal women.  
All  women had a BMI > 27 kg/m2 and did not participate in regular physical activity (<2 
exercise periods per week).  Body composition was measured via DEXA and CT scans.   
The average CRP for the group was 3.20 mg/L.  CRP levels were positively and 
significantly associated with body weight, BMI, fat mass and fat free mass, intra-
abdominal adipose tissue and triglycerides.  There was a significant, negative correlation 
between CRP and insulin sensitivity (measured as glucose disposal via hyperinsulinemic-
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euglycemic clamp). Multiple regression analysis revealed that body weight was the best 
predictor of CRP levels, explaining 18.1% of the variance. 
The relationship between CRP, obesity, and the insulin resistant syndrome were 
investigated in 186 age-matched premenopausal and postmenopausal women.  
Regression coefficients showed that measures of obesity, i.e. BMI, waist and hip 
circumference, and waist-hip ratio, significantly correlated with levels of CRP.  
Association was the strongest for waist and hip circumference.  After adjustment for 
BMI, waist circumference was the only measurement significantly associated with CRP.  
Additionally, waist circumference was the strongest predictor of CRP levels, accounting 
for 31.3% of the variance.  This suggests that abdominal fat accumulation may be an 
important factor for the cardiovascular inflammatory response.  Further analysis revealed 
that CRP levels were also associated with parameters of the insulin resistance syndrome: 
blood pressure, insulin, HDL-c, and triglycerides (Hak et al, 1999). 
Furthermore, Rawson et al (2003) found that in a cross-sectional analysis of men 
and women, CRP was significantly related to BMI (measures were averaged over the 
course of the year).  When subjects were distributed into tertiles based on BMI, mean 
CRP was significantly greater in obese (BMI >30 and mean CRP 3.2 mg/L) and 
overweight (BMI 25-29.9 and mean 2.1 mg/L) subjects.  In this cohort, there was no 
significant association between level of physical activity (assessed by three 24 hour 
physical activity recalls where amount and intensity of activity was converted into MET 
levels) and CRP, thus the authors concluded that BMI, not physical activity, is an 
independent predictor of CRP levels. It must be noted that this lack of association can not 
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be extended to level of physical fitness since physical activity was measured based on 
activity recall and actual fitness level was not assessed.  Previous studies finding a 
positive correlation between fitness and CRP often use maximal or sub-maximal testing. 
Overall, a clear positive relationship exists between CRP and body composition and/or 
adiposity. 
CRP,  gender and ethnicity 
 Several studies have shown that CRP levels are higher in females than males. 
Additionally, there seems to be a significant difference in CRP across different ethnic 
groups.  Marcell et al (2005) demonstrated a gender difference in CRP levels in a group 
of overweight (mean BMI 33.7 ± 4.8 kg/m2) middle-aged men and women. Results 
showed a significant positive correlation between CRP and % body fat (determined by 
DEXA) in women only.  After comparing CRP between men and women, women’s CRP 
was greater than 2-fold higher than men’s, indicating gender may play a role in CRP.  
Khera  et al  (2005) divided CRP values into low (< 1 mg/L), medium (1-3 mg/L) 
and high (>3 mg/L) in a group of men and women to investigate gender differences.  
Based on this division, women consisted of 40.7%, 41.9% and 61.9% of the groups, 
respectively.  Based on the same division, African-Americans consisted of 25.8%, 24.3% 
and 32.3% of the groups, respectively.  More specifically, 63.4% of African-American 
women had CRP levels > 3 mg/L compared to 50.4% of African-American men, 42.3% 
of Caucasian women and 29.1% of Caucasian men.  
Lakoski et al (2006) found that a CRP cutoff of 3 mg/L was the 75th percentile for 
men and 55th percentile for women.  The 75th percentile cutoff for women was 5 mg/L 
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and 21% of all women had a CRP level > 10 mg/L.  More specifically, the 75th percentile 
cutoff for African-American women was 7.5 mg/L. Furthermore, Heilbronn et al (2001) 
found in a population of obese women (BMI > 28 kg/m2), that 74% of  their CRP levels 
were > 3 mg/L.  
Participants in the women’s health study (mean age of 54.6 ± 7.1) were stratified 
by race to investigate ethnic differences in CRP, metabolic and lipid parameters. Analysis 
included 24,455 Caucasian (CC) and 475 African American (AA) women. Results 
showed that AA women were more likely to have higher BMIs and more likely to have 
diabetes.  CRP levels in AA women (median 2.96 mg/L) were significantly higher 
(44.6%) compared to CC women (median 2.02 mg/L).  After adjusting for age, smoking, 
diabetes status, alcohol use, hypertension, exercise, family history of myocardial 
infarction, estrogen use, education, and lipid levels the differences between the two 
groups remained.  When adjusted for BMI (this also included age and estrogen use), there 
was still a significant difference between the two groups, but the difference dropped from 
44.6% (unadjusted) to 10.6%.  It is clear that BMI has an effect on the differences in CRP 
among these two ethnic groups (Albert et al, 2004). 
Lamonte et al (2005) investigated the association between fitness, CRP and 
metabolic syndrome in a racially diverse sample of women.  Results indicated that for 
BMI, waist circumference, insulin, homeostasis model assessment of insulin resistance 
(HOMA-IR), CRP, and percent abdominal obesity, CC women had significantly lower 
values than AA women. Additionally, in AA women compared to CC, the prevalence of 
metabolic syndrome was 29.5% vs. 8.9%, elevated CRP levels (> 2.0 mg/L) was 70.5% 
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vs. 28.2%, and both metabolic syndrome and elevated CRP levels was 22.7% vs. 4.3%.  
These results show that the prevalence of metabolic syndrome and/or elevated CRP is 
significantly higher in AA women versus CC in this cohort (Lamonte et al, 2005). 
Forty-four AA and forty-six CC women were assessed during the Cross-Cultural 
Activity Participation Study.  Overall, AA women had significantly higher BMI, waist 
circumference and insulin, but had significantly lower fitness levels compared to CC 
women.  Within this study, CRP correlated significantly with fitness (defined as amount 
of time spent on treadmill during graded exercise test), BMI, waist circumference, 
insulin, and triglycerides across both ethnic groups.  The mean CRP level was 
significantly higher in the AA women (LaMonte et al, 2002). 
Effects of exercise on CRP 
Research investigating the relationship between CRP and physical activity is 
inconclusive.  It has been shown that females with higher CRP values have significantly 
lower estimated VO2max (Kuo et al, 2006). Kondo et al (2005) investigated the 
relationship between CRP and estimated maximal oxygen uptake.  Subjects included 50 
healthy, middle-aged men and women. Body fat (measured via skinfold thickness), body 
weight, BMI, glucose, insulin, insulin resistance (HOMA-IR), lipids, and CRP were 
measured.  Analyses showed that CRP was positively correlated with percent body fat, 
BMI, and HOMA-IR.  CRP was negatively correlated with HDL-c and estimated 
maximal oxygen uptake.  In multivariate analysis, estimated maximal oxygen uptake was 
an independent factor for CRP, suggesting that increased physical activity alone might 
decrease CRP levels, improving inflammation. 
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Women with Type 2 diabetes were assessed for cardiorespiratory fitness and 
divided into low (LCF) and average (ACF) cardiovascular fitness groups (determined via 
VO2peak performance), (difference in group averages, p<0.05).  In addition, eight healthy 
older women without Type 2 diabetes were used as controls.  There were no differences 
in classic markers of CVD (i.e. total cholesterol, HDL, LDL, and triglycerides) between 
LCF and ACF groups, but the LCF group had a significantly higher CRP level (mean 6.3 
mg/L) than the ACF group (mean 1.9 mg/L).  There were no differences in CRP values 
between the ACF and control groups.  Within the groups, there was a significant positive 
correlation between CRP and HOMA-IR   This study shows that high CRP levels are 
associated with lower fitness levels and HOMA-IR values (McGavock et al, 2004).  
In an elderly population (greater than 70 years), a cross-sectional study examined 
the association between physical activity and markers of inflammation.  Traditional, 
structured exercise done by the participants was divided into none, low (>0 to < 180 
min/wk), and high (≥ 180 min/wk). Results indicated that CRP levels were significantly 
lower in the high exercise group.  These significant results were found after adjusting for 
age, sex, and race and were still significant after further adjustment for smoking, alcohol, 
use of anti-inflammatory drugs and antioxidants, hypertension, arthritis, cardiovascular, 
cerebrovascular and peripheral vascular disease, osteoporosis, diabetes, respiratory 
disease and acute upper respiratory tract infection.  However, when adjustments for total 
and visceral body fat (measured via DEXA and CT) were added, significant differences 
were lost (p = .096) (Colbert et al, 2004). 
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 To further investigate the relationship between fitness levels and body 
composition with CRP, models were used that adjusted for all other covariates noted 
above.  There was a significant relationship between BMI and CRP levels, but no 
significant interaction between BMI and exercise for CRP. These results suggests that 
body fat and not amount of physical activity is most important in predicting CRP levels 
(Colbert et al, 2004).     
In contrast, several studies have shown that an increase in activity leads to a 
decrease in CRP levels.  In a recent adolescent study, subjects which included 21 male 
and female, age 15-16 years, were divided into lean and obese groups.  The obese 
adolescents were matched and randomized in to a control or physical activity-behavioral-
diet based lifestyle intervention group.  The treatment group participated in 45 minutes of 
physical activity three times a week.  In addition to the activity regimen, their diet and 
everyday activity was modified.  For example, meal portion were reduced, sugar-based 
drinks were reduced, and television time was limited.  During this 3 month study, both 
the obese and lean control groups did not make any other activity or lifestyle changes 
(Balagopal et al, 2005). 
 Baseline measurements were used to compare all obese subjects to the lean 
subjects.  CRP, BMI and percent body fat were all significantly higher in the obese 
adolescents.  Furthermore, the obese group had a significantly higher calculated HOMA-
IR compared to the lean subjects.  At baseline, CRP was significantly correlated with 
BMI, percent body fat, and calculated HOMA-IR (Balagopal et al, 2005). 
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 Comparing the obese intervention group against the obese control group, the 
intervention group maintained their body weight while the control group had a significant 
gain in body weight and percent body fat.  The intervention group had a significant 
decrease in percent body fat and increase in fat free mass (measured via DEXA).  In the 
intervention group, there was a significant decrease in calculated HOMA-IR.  CRP 
decreased by 20-62% in seven of the eight subjects and the overall mean decrease was 
~30% (p = .02).  Changes in fitness level were not reported.  This study shows that the 
obesity-related inflammatory process can start early in adolescences and can be reversed 
through early lifestyle intervention (Balagopal et al, 2005). 
Oberbach et al (2006) looked at the effects of 60 minutes of exercise, three times 
a week for four weeks on CRP in a group stratified by glucose tolerance.  Subjects were 
classified as normal glucose tolerant, impaired glucose tolerant, or type 2 diabetic.  After 
4 weeks of training, all three groups decreased CRP levels, percent body fat, BMI, waist-
to-hip ration and increased VO2max.  In this population, CRP was significantly, 
positively correlated with percent body fat, BMI, glucose and insulin and negatively 
correlated with VO2max. 
Jae et al (2006) investigated the effects of a lifestyle intervention, consisting of 
exercise training, on CRP, obesity measures and fitness levels.  The intervention 
consisted of 50-60 minutes of home-based exercise, 60-80% maximum heart rate, 5 times 
per week for 3 months.  In addition, the participants attended diet education sessions and 
met with a physiologist every 2 weeks to monitor their progress.  The control group 
received no education or exercise intervention.  After 3 months of treatment, there was a 
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significant decrease in body weight, BMI, and CRP levels and a significant increase in 
VO2peak.  Further analysis revealed that improved VO2peak and weight loss were 
independent predictors of decreasing CRP levels. 
A group of Japanese women (both pre- and postmenopausal) underwent a 2 
month long aerobic exercise program to assess the effects of exercise on inflammatory 
markers.  The subjects participated in 2 structured workouts per week that lasted 110 to 
140 minutes.  These sessions consisted of 80 minutes of aerobic dance followed by 30-60 
minutes of bicycle or treadmill exercise.  In addition, they were asked to perform home-
based exercise one or more days per week.  At baseline, CRP was significantly positively 
correlated to body weight, BMI, waist-hip ratio, total cholesterol, LDL cholesterol, 
triglycerides, fasting glucose and insulin, HOMA-IR, and HbA1c.  CRP was significantly 
negatively associated with HDL-c and peak oxygen uptake (Okita et al, 2004).   
After 2 months of training, BMI, waist-hip ratio, body weight, lipid and glycemic 
measures and CRP levels were significantly reduced and fitness levels were improved 
(significance not reported). Further analysis showed that percent weight reduction 
significantly correlated with changes in lipid (except HDL-c) and glycemic measures, but 
decreases in CRP were not proportional with changes in body weight.  It must be noted 
that the average CRP at baseline in this group was much lower (0.60 mg/L with 
interquartile range of 0.26-1.16) than seen in previous studies of sedentary, overweight 
individuals. Since CRP levels greater than 3.0 mg/L are considered high, it may be that 
there was no association with changes in body weight in this study because the CRP 
levels in these women were not elevated enough.  In addition, the quartile with the largest 
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weight reduction did not have significant decreases in CRP.  Again, the authors suggested 
that adverse effects of strenuous exercise and high pace weight reduction may include 
increases in inflammation, canceling out any improvements in CRP (Okita et al, 2004). 
Marcell et al (2005) set out to determine the effects of different exercise regimens 
on CRP levels and to assess whether or not exercise-induced changes in insulin 
sensitivity was partially explained by changes in inflammatory markers.  Fifty-one 
Caucasian, middle aged, sedentary men and women were randomized based on sex and 
insulin sensitivity (measured via euglycemic hyperinsulinemic clamp) into 2 different 
exercise groups or a control group.  The exercise groups participated in 30 minutes of 
activity 5 days per week for 16 weeks.  The exercise intervention was divided into a 
moderate intensity group with no specific heart rate requirements and an intense group 
defined as 80-90% of age-predicted maximal heart rate. 
After the intervention, both the moderate and intense groups had a significant 
decrease in body weight, percent body fat (measured via DEXA), and BMI compared to 
the control group.  Only the intense exercise group had a significant increase in insulin 
sensitivity and predicted VO2 max compared to the other two groups.  This study 
revealed no changes in CRP after exercise in either group.  To further investigate this 
lack of effect, the subjects were divided into tertiles based on absolute change in 
VO2max.  There was still no change in CRP associated with improved fitness.  Finally, 
subjects were divided into tertiles based on changes in body fat.  The group with the 
greatest body fat loss (average 4% decrease) had a significantly greater percent change in 
insulin sensitivity than the other two groups, but there were still no changes in CRP.  The 
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lack of differences between groups may be partially attributed to the fact that the control 
group decreased CRP levels by 1.0 ± 0.5 mg/L, the same decrease seen in the moderate 
exercise group.  However, it is still surprising that the intense exercise group only 
decreased CRP levels by 0.4 ± 0.5 mg/L (Marcell et al, 2005). 
In general, the results from this study suggest that moderate to intense exercise 
associated with a decrease in body weight, was not associated with a reduction in CRP, 
even when subjects were stratified by changes in fitness level and body fat.  The authors 
suggest that weight loss was not great enough to see a reduction in CRP as seen in other 
studies and that calorie restriction may be needed.  Furthermore, the fact that exercise 
itself has an inflammatory component may mask the effects of exercise on CRP if weight 
loss is not significant enough (Marcell et al, 2005). 
Effects of diet-induced body weight changes on CRP 
Some research indicates that changes in CRP are mostly due to reductions in body 
weight and/or fat mass and not to physical activity in and of itself.  Twenty-five women 
underwent a weight loss protocol that consisted of 1200 kcal/day with no change in 
physical activity.  This portion of the study lasted approximately 14 months.  These 
women lost an average of 14.5 ± 6.2 kg of body weight (p < 0.0001), with a 25% loss in 
fat mass (kg).  Weight loss was accompanied by a decrease in triglyceride levels and an 
increase in HDL-c and glucose disposal.  There was a 32.3% reduction in CRP levels, 
with the average values decreasing from 3.06 to 1.63 mg/L.  Changes in body weight and 
fat mass were significantly correlated with a reduction in CRP even after adjustments for 
hormone replacement, aspirin, and statin use (Tchernof et al, 2002). 
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Heilbronn et al (2001) investigated CRP measures in an obese population of 
women (BMI > 28 kg/m2) after 12 weeks of calorie restriction.  Subjects ate a diet of 
1350 kilocalories/day with no change in their physical activity.  At baseline, CRP levels 
in 74% of the women were greater than 3.0 mg/L and CRP was associated with waist 
circumference and BMI.  At baseline, there was no association between fasting glucose 
and lipid levels and CRP.  
After treatment, there was a mean decrease in body weight by 7.9 kgs.  Total 
cholesterol, LDL-c and triglyceride levels were significantly reduced.  There was a 
significant reduction in CRP and this reduction was correlated with overall weight loss, 
percentage weight loss, and baseline CRP levels.  After weight loss, CRP was 
significantly correlated with BMI, waist and hip circumference, and triglycerides and 
change in CRP was correlated with change in total cholesterol (Heilbronn et al, 2001).  
These results strengthen the idea that a decrease in CRP is more closely related to 
changes in body composition rather than increase physical activity and/or improvements 
in fitness.   
 
Plasminogen Activator Inhibitor-1 (PAI-1) 
Type 1 PAI, or endothelial, is a single chain glycoprotein belonging to the serpin 
superfamily.  It is synthesized in its active form and will remain this way if it binds to 
vitronectin, stabilizing the inhibitor.  The synthesis of PAI-1 is increased by endotoxin, 
growth factors, hormones and cytokines (Juhan-Vague, 1999).  PAI-1 is found in the 
blood in platelets (100-200 ng/ml) and in plasma (10-20 ng/ml).  The levels of PAI-1 in 
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plasma can be measured as either antigen (ng/ml) or activity (units/ml).  PAI-1 antigen 
levels are measured in plasma via ELISA with an antibody and activity is measured by a 
tPA coated ELISA, which assess PAI-1 binding.  Both are highly correlated and either 
can be used for measurement purposes.  Both PAI-1 activity and antigen fluctuates with  
circadian rhythm, with the highest measurements seen in the early morning (Kluft et al, 
1988, Juhan-Vague et al, 1992).   
The modulation of PAI-1 influences fibrin and extracellular matrix accumulation 
(Juhan-Vague et al, 1999).  The fibrinolytic system dissolves fibrin deposits and disrupts 
blood coagulation, participating in lysis of intravascular thrombi.  It is a proteolytic 
system in which plasminogen is converted to plasmin, often on the surface of thrombi, 
via tissue-type plasminogen activators (t-PA) or urokinase-type plasminogen activators 
(u-PA).  Plasmin is a trypsin-like enzyme that degrades fibrin and extracellular matrix 
proteins. Degradation of fibrin is decreased with increased PAI-1 activity (Lindahl et al, 
1996, Speiser et al, 1988).   
t-PA is implicated in the degradation of intravascular fibrin and u-PA is produced 
mainly by macrophages and is implicated in tissue remodeling (Alessi et al, 2000).  t-PA 
and u-PA are inhibited by PAI-1, and the modulation of PAI-1 influences fibrin and 
extracellular matrix accumulation thus making PAI-1 the main regulator of plasminogen 
activation and the fibrinolytic system.  PAI-1 binds to t-PA or u-PA, forming an inactive 
complex, which is cleared from the system via the liver (Juhan-Vague et al, 1999, Mavri 
et al, 2004, Speiser et al, 1988).   
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PAI-1 
 
In a normal system, there is an equilibrium between anticoagulant protease 
inhibitors (i.e. PAI-1) and activation of blood coagulation (often at the site of endothelial 
injury or inflammation). With elevated PAI-1 levels, there is excessive inhibition on t-PA 
and u-PA so that plasminogen does not convert to plasmin.  Plasmin cannot degrade 
fibrin and the degradation of extracellular matrix is decreased.  An excess of PAI-1 leads 
to hypofibrinolysis which decreases thrombolysis, diminishing the removal of thrombi, 
leading to a cardiovascular event (Lindahl et al, 1996, Mavri et al, 2004, Speiser et al, 
1988). 
PAI-1 and atherosclerosis 
PAI-1 not only decreases fibrin degradation, but also influences cell adhesion and 
migration.  This occurs because of the action of PAI-1 on uPA receptors (uPAR), 
specifically on smooth muscle cells (SMC).  SMC migration requires cellular expression 
of integrins and vitronectin in the matrix.  PAI-1 promotes u-PA clearance from its 
receptors which then decreases the interaction of uPAR with vitronectin.  PAI-1 also 
directly interferes with uPARs interaction with vitronectin by acting as a competitive 
inhibitor for vitronectin. When PAI-1 is present, it inhibits the attachment of integrin to 
plasmin 
t-PA or u-PA 
plasminogen 
fibrinogen fibrin Fibrin-degradation products 
inhibits 
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vitronectin, which is necessary for SMC migration.  These processes allow PAI-1 to 
influence the tissue remodeling processes, specifically cellular adhesion, migration and 
proliferation (Juhan-Vague et al, 1999, Stefansson and Lawrence, 1996). 
The presence of atherosclerotic plaques are positively correlated with an increase 
in PAI-1 expression.  Schneiderman et al (1992) studied gene expression of PAI-1 in 
sections of human atherosclerotic arteries.  Results indicated that PAI-1 mRNA was 
significantly increased in atherosclerotic arteries as compared to normal or mildly 
affected vessels.  In situ hybridization also revealed an intense signal for PAI-1 mRNA in 
cells surrounding plaque. Since it is known that PAI-1 is deposited into the extracellular 
matrix on smooth muscle and endothelial cells and preserves matrix structures from 
degradation (Mimuro et al, 1987), these authors suggest PAI-1 may play a significant 
role in the organization and incorporation of thrombi by limiting extracellular proteolysis 
in developing plaque lesions (Schneiderman et al, 1992).  
Within SMCs, PAI-1 is significantly expressed in the fibrous cap.  It is also 
detected in the area surrounding the necrotic core in macrophages.  This evidence 
suggests that PAI-1 expression plays a role in thrombotic complications and extracellular 
matrix deposits (Lupu et al, 1993). 
Some studies show that an increase in PAI-1 is predictive of cardiovascular events 
and mortality.  Within a group of 109 men with a myocardial infarction before the age of 
45, 16 men had at least one reinfarction and PAI-1 was independently related to 
reinfarction (Hamsten et al, 1987).   
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The ECAT (European Concerted Action on Thrombosis and Disabilites) Angina 
Pectoris Study followed patients for two years and compared subjects who had undergone 
coronary angiography who did or did not have a major coronary event (defined as sudden 
coronary death, and fatal and nonfatal myocardial infarctions).  PAI-1 antigen and 
activity were significantly higher in the coronary event group.  However, the significant 
differences between the means were washed out after adjusting for variables related to 
insulin resistance (triglycerides, HDL-c, BMI, systolic blood pressure, history of 
diabetes).  In addition, correlational analysis showed a strong correlation between PAI-1 
antigen and activity to BMI and triglyceride levels.  In conclusion, the authors state that 
increased levels of PAI-1 antigen and/or activity are associated with an increase risk of 
subsequent coronary events (Juhan-Vague et al, 1996).  
PAI-1 and metabolic disorders 
Many studies have shown that PAI-1 plasma levels are strongly positively 
associated with insulin resistance syndrome and its parameters.  Festa et al (2006) found 
that higher levels of PAI-1 over time are associated with a higher incidence of type 2 
diabetes, independent of body weight and insulin resistance, and after adjusting for 
demographics, smoking, and baseline PAI-1 levels.  Vague et al (1986) found that BMI 
and insulin were significantly, positively correlated with PAI-1 levels.  Furthermore, 
stepwise analysis showed that these correlations were independent (Vague, et al, 1986).  
This is further supported by Eliasson et al (1994) who found that insulin levels are a 
strong predictor of PAI-1 activity.  In addition, those with impaired glucose tolerance 
(measured via oral glucose tolerance test) tend to have increased PAI-1 activity. 
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 Lindahl et al (1996) compared fibrinolytic activity to insulin resistance (via 
HOMA-IR), insulin sensitivity index (ISI), and fasting insulin levels in men and women.  
In both genders, PAI-1 activity was significantly positively correlated with fasting insulin 
and HOMA-IR and was significantly negatively correlated with ISI.  When insulin 
resistance measures were divided into tertiles, there was a dose response.  Men with the 
highest insulin resistance (upper tertile) had three times the PAI-1 activity compared to 
those in the lowest tertile, and in women PAI-1 activity was twice as high in the upper 
compared to lower tertile.  Using multiple regression, HOMA-IR, triglycerides, DBP, and 
age significantly accounted for 42% of the variance for PAI-1 activity in men.  In 
women, only HOMA-IR and BMI significantly accounted for 30% of the variance in 
PAI-1 activity (Lindahl et al, 1996). 
Potter van Loon et al (1993) administered a hyperinsulinemic euglycemic clamp 
to obese nondiabetics and obese type 2 diabetics.  Results showed that PAI-1 antigen was 
significantly related to level of insulin resistance.  The combination of hepatic and 
peripheral insulin action, insulin and triglyceride levels, blood pressure, WHR, and BMI 
accounted for 76% of the variance of PAI antigen.  The authors concluded that elevated 
levels of PAI-1 contribute to the increased risk of cardiovascular risk associated with 
insulin resistance. 
In general, persons with type 2 diabetes have a higher BMI and higher levels of 
insulin, glucose, triglycerides, and total cholesterol and lower levels of HDL-c compared 
to those without type 2 diabetes.  Additionally, PAI-1 activity has been found to be 
significantly higher (mean 21.8 units/ml) in the type 2 diabetics than in non-diabetics 
 35
 
(mean 7.7 units/ml).  Correlation analysis showed that PAI-1 activity was significantly 
correlated with BMI and insulin and apolipoprotein B levels.  However, partial 
correlation analysis showed that after adjustment for insulin, both BMI and 
apolipoprotein B levels no longer correlated with PAI-1 activity.  Furthermore, the 
presence of coronary heart disease was associated with higher levels of PAI-1 activity 
(Juhan-Vague et al, 1989). 
The Insulin Resistance Atherosclerosis Study (IRAS) examined subjects across 
different ethnic groups with varying states of glucose tolerance (measured via frequently 
sampled intravenous glucose tolerance test with minimal model analysis).  Subjects were 
divided into one of three groups: normal glucose tolerance (NGT), impaired glucose 
tolerance (IGT) and type 2 diabetes (DM).  Mean PAI-1 antigen levels for the NGT, IGT, 
and DM were 19.8 ng/ml, 26.6 ng/ml, and 31.9 ng/ml respectively.  PAI-1 antigen was 
significantly different between all three groups before and after adjustment for BMI, age, 
sex and ethnicity.  However, after adjustment for insulin sensitivity, there were no longer 
significant differences between NGT and IGT groups.  Differences between NGT and 
DM and IGT and DM remained significant (Festa et al, 1999). 
PAI-1 antigen was significantly correlated with BMI, fasting insulin, proinsulin 
and insulin sensitivity within all groups.  Even after adjustment for age, sex, ethnicity, 
BMI, and glucose tolerance, PAI-1 antigen was still significantly correlated with fasting 
insulin, proinsulin, and insulin sensitivity.  This association of PAI-1 antigen and insulin 
and proinsulin remained after insulin sensitivity was factored into the model (Festa et al, 
1999). 
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The multiple regression model suggested that BMI, insulin sensitivity, proinsulin, 
and fasting insulin were significant independent predictors of PAI-1 antigen and together 
accounted for 34.2% of the total variance.   Furthermore, proinsulin levels were a 
stronger predictor than fasting insulin concentrations.  This study demonstrates a positive 
relationship between insulin and it precursors and PAI-1 antigen levels.  This association 
was found across varying states of glucose tolerance and was independent of insulin 
sensitivity.  In addition, BMI and insulin sensitivity were found to have a significant 
relationship to PAI-1 antigen.  Since BMI, glucose tolerance and fasting insulin levels are 
all variables associated with the insulin resistance, PAI-1 antigen may also be a 
contributing factor in insulin resistance (Festa et al, 1999). 
A PAI-1 knockout mouse (-/-) model has been used to describe the relationship 
between PAI-1, obesity and insulin resistance markers.  A euglycemic-hyperinsulinemic 
clamp was performed at baseline and at 12 weeks post-high fat diet.  The control mice 
developed hyperglycemia, hyperinsulinemia, and hyperleptinemia in response to the 
high-fat diet, but the PAI -/- mice did not.  In addition, glucose infusion rates to maintain 
euglycemia in the PAI -/- mice was significantly higher that in the controls, suggesting 
better insulin sensitivity.  This suggests that a deficit in PAI-1 is helpful in protecting 
against diet-induced metabolic abnormalities (Ma et al, 2004).        
PAI-1 and obesity 
Obesity can be defined as the accumulation of excess body fat and PAI-1 seems to 
be linked to obesity.  When women with different waist to hip circumference ratios 
(WHR) were matched with respect to age, body weight, lean body mass and body mass, 
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results indicated that women with elevated WHR also had elevated PAI-1 levels 
compared to those with low WHR (Landin et al, 1990). 
In addition, it has been shown that weight loss, independent of triglyceride and 
insulin changes, is accompanied by a reduction in PAI-1 levels.  When subjects 
underwent significant weight loss (7.4 kg in women and 9.4 kg in men), there was a 
significant reduction in mean PAI-1 antigen.  There was a dose-dependent association 
between the degree of weigh-loss and decrease in PAI-1 antigen (Folsom et al, 1993).   
It is generally accepted that PAI-1 is expressed mostly at the liver. However, 
expression at the adipose tissue may explain the correlation between changes in body 
weight and fatness and PAI-1.  To investigate this hypothesis, Shimomura et al (1996) 
examined rat PAI-1 mRNA in fat tissue.  PAI-1 mRNA expression was found in both 
visceral and subcutaneous fat.  With the development of obesity over time (via 
ventromedial hypothalamus lesion), PAI-1 mRNA expression increased in visceral fat, 
but not in subcutaneous fat or the liver.  Overall, PAI-1 mRNA was more abundant in 
visceral fat than in subcutaneous fat and liver.  In support of these results, Bastelica et al 
(2002) found that in vivo visceral fat expressed almost 5-fold more PAI-1 mRNA than 
subcutaneous fat.   These results suggest that visceral adipose tissue is an important factor 
in PAI-1 expression in obesity. 
Furthermore, Shimomura et al (1996) looked at the expression of PAI-1 in 
different types of adipose tissue.  In obese and non-obese subjects, the level of PAI-1 was 
significantly associated with the visceral fat area and not the subcutaneous fat area 
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(measured via computed tomography).  When gender was factored in, these significant 
differences remained.  
Histochemical studies have revealed interesting results concerning adipose tissue 
and PAI-1.  When entire adipose tissue is analyzed for PAI-1 mRNA, little to no signal 
was detected.  However, when tissue is broken down, the stromal cells elicited a much 
stronger signal than the adipocyte fractions.  On the other hand, when adipocytes were 
incubated, they were the main source of PAI-1 synthesis.  This suggests that adipocytes 
are the main source of PAI-1 synthesis under specific environmental conditions.  
Increased PAI-1 expression was found in both subcutaneous and omental fat, but omental 
tissue produced more PAI-1 than subcutaneous under incubation (Alessi et al, 1997). 
These findings are important since it is known that intra-abdominal visceral fat is a better 
indicator of heart disease than overall fat mass (Nakamura et al, 1994).   
PAI-1, gender and ethnicity 
 Research examining gender and ethnic difference in PAI-1 are limited and 
inconclusive.  Women tend to have higher fibrinogen levels than men and this elevation 
in fibrinogen is significantly associated with insulin resistance and hyperinsulinemia 
(Lindahl et al, 1996).   
Toft et al (1997) investigated gender differences in a group of stable, untreated 
hypertensive patients.  Age-adjusted correlations were run between several metabolic 
parameters and PAI-1 activity. In men, plasma glucose and insulin sensitivity index (ISI) 
were significantly associated with PAI-1 activity.  In women, BMI, WHR, plasma 
glucose, insulin, proinsulin, c-peptide, ISI, and serum triglycerides and VLDL cholesterol 
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were significantly associated.  Subjects who were glucose intolerant (measured via oral 
glucose tolerance test) had significantly higher PAI-1 activity, (p=0.04). When BMI and 
WHR ratio were correlated with metabolic parameters, only plasma glucose and insulin 
were significantly associated with PAI-1 activity in both genders. There were no 
difference in PAI-1 activity between males and females (Toft et al, 1997).  In multiple 
stepwise regression analysis, plasma glucose, and age were significantly associated with 
PAI-1 and accounted for most of the variance in men.  Neither WHR nor BMI was 
associated with PAI-1 activity in men.  In women, insulin sensitivity accounted for most 
of the variability.  BMI and WHR and to some degree ISI, were strong determinants of 
elevated PAI-1 activity in women and not men.  Even though there were no gender 
differences, levels of PAI-1 activity in males and females are influenced by different 
factors (Toft et al, 1997).  
Furthermore, van Harmelen et al (2000) found no difference in PAI-1 secretion in 
adipose tissue between men and women.  They did find that plasma PAI-1 activity levels 
were higher in men than women, but this significance was lost when waist-to-hip ratio 
was factored in.  In contrast, Mansfield et al (1996), found that PAI-1 activity was 
significantly higher in females than males in a population of type 2 diabetics.  Even when 
BMI, glycosylated hemoglobin, and cholesterol were factored in, sex remained an 
independent predictor of PAI-1 activity level. 
Festa et al (2003) investigated ethnic differences in plasma PAI-1 levels and 
genetic polymorphisms.  African-Americans had a lower prevalence of the 4G/4G and 
4G/5G genotypes that are often associated with higher PAI-1 levels.  In addition, PAI-1 
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antigen levels were significantly lower in African-American (13.38 ng/ml) than non-
Hispanic whites (18.19 ng/ml). 
To further explore ethnic differences in PAI-1 and obesity, Solano et al (2003) 
compared obese and overweight African American (AA) and Caucasian (CC) 
premenopausal women.  All subjects had BMI > 25 kg/m2 and were in good health and 
both groups had comparable levels of physical activity and nutrient intake.  There were 
no differences between AA and CC women in BMI, fat mass and % body fat (measured 
via BIA).  However, AA women had a significantly lower visceral adipose tissue (VAT), 
area and volume (measured via MRI).  In addition, AA women had significantly lower 
levels of triglycerides than CC women and there were no differences in other lipid 
measures, insulin, glucose, HOMA-IR, leptin, or PAI-1 antigen.  Mean (SD) PAI-1 levels 
were 44.8 (± 29) ng/ml in Caucasian women and 48.1 (32) ng/ml in African-American 
women.  
Correlational analysis showed that PAI-1 was significantly correlated with 
HOMA-IR and fasting insulin in all women.  However, after adjusting for age and fat 
mass, this association was lost in the CC women but not in the AA women.  After the age 
and fat mass adjustment, PAI-1 was significantly related to VAT volume, DBP, 
triglycerides, HDL, and glucose in the CC women only.  No other significant partial 
correlations were found in the AA women other than insulin and HOMA-IR (Solano et 
al, 2003). 
Multiple regression analysis that adjusted for age, HOMA-IR glucose and 
triglycerides revealed that VAT volume was the only independent predictor of PAI-1 in 
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CC women.  In AA women, HOMA-IR was the only independent predictor of PAI-1 and 
explained 30.6% of the variance.  This study showed a lack of association between PAI-1 
and visceral adiposity in AA women.  This may suggest that in African-American 
women, insulin resistance (measured via HOMA-IR) is associated with elevated PAI-1 
and not obesity itself in AA women, whereas in CC women, VAT volume seems to play 
a major role in PAI-1 levels.  This suggests that there may be an ethnic difference in the 
pathophysiologic impact of VAT (Solano et al, 2003).   
Effects of exercise on PAI-1 
It has been proposed that regular physical activity can deter age-related effects of 
the fibrinolytic system.  DeSouza et al (1998) examined the differences in fibrinolytic 
variables in young and old sedentary and physically active women.  Old sedentary 
women had significantly higher levels of PAI-1 antigen and PAI-1 activity than young 
sedentary women, suggesting an age factor in levels of PAI-1.  There were no differences 
in PAI-1 antigen and PAI-1 activity between young active and old active women, 
however young and old active women had significantly lower levels of both compared to 
there age-matched counterparts.  This suggests that physical activity may prevent the 
decline in fibrinolytic function associated with aging. 
Several studies have investigated the effect of  physical activity on PAI-1.  Fifty-
two obese (BMI ≥ 25 kg/m2) and nineteen lean premenopausal women were recruited to 
participate in a body weight reduction program.  At baseline, the obese women had 
significantly higher BMI, estimated % body fat ([0.439 x waist circumference in cm] + 
[0.221 x age in years] – 9.4), and insulin, triglyceride, leptin and PAI-1 antigen.  In 
 42
 
addition there was a significant correlation with PAI-1 activity and antigen and BMI, 
wait-to-hip ratio, estimated % body fat, triglycerides, glucose, insulin, and leptin levels 
(Marvi et al, 1999). 
The weight reduction program consisted of a low-calorie diet and physical 
activity prescribed as two ten minute aerobic bouts a day and 1 hour of supervised 
activity twice a week.  After one week of the program, there was a 31% decrease in PAI-
1 activity and 26% reduction in PAI-1 antigen (p<0.01).  At the end of the program (10-
12 weeks), there was a significant decrease in BMI, WHR, % body fat, glucose, leptin, 
and PAI-1 activity and antigen.  PAI-1 activity and antigen was reduced to the levels seen 
in the lean controls and PAI-1 activity actually became lower than observed in the lean 
controls.  Overall, PAI-1 activity decreased by 74% and antigen decreased by 54%.  At a 
5 month follow-up, those who regained greater than 25% of their weight had a significant 
increase in PAI-1 and activity, which paralleled the increase in BMI (Marvi et al, 1999). 
Correlation coefficients revealed that change in PAI-1 activity and antigen were 
significantly related to change in BMI, % body fat, insulin and leptin at the end of the 
program.  At the 5 month follow-up, change in PAI-1 activity was significantly related to 
change in BMI and % body fat, whereas PAI-1 antigen was only related to change in % 
body fat.  Multiple regression analysis revealed that only changes in BMI were 
significantly and independently associated with changes in PAI-1 and accounted for 34% 
of the variance.  This study showed that a reduction in body weight resulted in a 
reduction in PAI-1 levels (Marvi et al, 1999). 
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In a group of obese subjects with impaired glucose tolerance, Lindahl et al  
(1999) administered an intense lifestyle intervention to assess changes in PAI-1 activity.  
Treatment subjects were admitted to a wellness center for one month and participated in 
an intense activity schedule of 2.5 hours of daily low-moderate activity.  In addition, 
subjects were subjected to a low-fat, high-fiber diet and counseled on lifestyle changes.  
The control group was only counseled and given written and oral instructions on lifestyle 
change. Twelve months from initial evaluation, subjects were called back in for a follow-
up.  At follow-up, the intense treatment group had significant changes in (group x time 
effect) in BMI, body weight, WHR, VO2 max, and PAI-1 activity. 
In a 10 week training study, post- and pre-menopausal women participated in 
aqua exercise and resistance training 3 days per week.  The training program resulted in a 
decrease in percent body fat and total fat mass (TFM, measured via BodPod), BMI, and 
PAI-1 antigen.  VO2max trended towards an increase, but was not significant.  The 
relationship of PAI-1 to fat mass was examined and found that the ratio of PAI-1/TFM 
significantly decreased.  However, further analysis revealed that there was no correlation 
between TFM and PAI-1 antigen or changes in PAI-1 antigen before or after training 
(Hayase et al, 2002).  
Although there is an obvious association between PAI-1 and exercise, limited 
research has attempted to explain the mechanisms behind it.  Specifically, can exercise 
decrease PAI-1 levels independent of body weight changes?  In an attempt to investigate 
this, Bodary et al (2003) examined the effects of short-term exercise on PAI-1 activity 
and antigen and other metabolic parameters, independent of body weight changes. 
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Thirty-two sedentary men and women between the age of 50 and 70 years 
participated in either an eleven day exercise protocol or were assigned to a control group.    
The exercise protocol was 50 minutes per day at 65% heart rate reserve.  There were no 
differences between the groups on any of the measures before or after exercise.  After 21 
days of training, neither resting levels of PAI-1 activity or antigen had changed.  This 
study design found no significant reductions in body weight or PAI-1 activity, suggesting 
that decreases in PAI-1 with exercise may be due to body weight changes and/or a more 
long-term training effect (Bodary et al, 2003). 
 
Relationship between CRP and PAI-1  
Devaraj et al (2003) has shown a significant relationship between levels of CRP 
and PAI-1.  CRP increases the expression of PAI-1 in human aortic endothelial cells 
(HACEs).  Incubation of HAECs with CRP resulted in a significant increase in PAI-1 and 
activity.  In addition, increased CRP caused a dose-dependent increase in intracellular 
PAI-1 protein and mRNA levels.  All of these effects were maximal at 12 hours of 
incubation.  These results suggest that CRP and PAI-1 may be closely linked in the 
progression of atherosclerosis. 
 
Lifestyle Activity Modification versus Structured Physical Activity 
 Past traditional exercise guidelines consisted of structured exercise of at least 60% 
of maximal oxygen uptake for up to 60 minutes, three times a week.  More recent 
guidelines introduced by the Centers for Disease Control and the American College of 
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Sports Medicine recommend that adults perform 30 minutes of continuous or 
accumulated, moderate-intensity physical activity most, if not all, days of the week (Pate 
et al, 1995, US Department of Health and Human Services, 1996).  There have been few 
randomized controlled studies investigating the differences between several short bouts 
of exercise (i.e. intermittent exercise) and long, continuous bouts of exercise (i.e. 
structured exercise) and their effects on cardiovascular fitness. 
Dunn et al (1999) investigated the hypothesis that lifestyle activity modification 
(LAM) results in higher levels of overall physical activity and improved cardiovascular 
risk factors at 24 months compared to baseline. Healthy sedentary men and women were 
divided into either a structured exercise protocol or a lifestyle physical activity program.  
Both groups underwent a psychological behavior change program.  For the first 6 
months, both groups took part in an intensive intervention and for the following 18 
months, a maintenance program was established.  The structured exercise group 
participated in exercise at 50-85% maximal aerobic power for 20-60 minutes on 3-5 days 
per week.  The LAM group was instructed to participate in 30 minutes of moderate-
intensity physical activity most, preferably all days of the week in a manner that was 
adapted to their individual lifestyle. 
 At baseline both groups were similar with a mean BMI of 28.4 and 28.0 kg/m2 
and a mean percent body fat of 31.5 and 30.9 for the LAM and structured exercise 
groups, respectively.   At 24 months, both groups significantly increased their VO2peak 
and energy expenditure, and decreased their percent body fat (measured via 7-site 
skinfold thickness) and overall blood pressure with no significant differences between the 
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groups.  Only the structured exercise group significantly decreased their total cholesterol 
and LDL-C and increased their HDL-C levels.  The structured exercise program 
decreased their body weight (kg) more than the LAM group, but not significantly.  The 
LAM group increased their moderate-intensity physical activities nearly 3 times that of 
the structured exercise group (Dunn et al, 1999). 
 This study illustrated that the LAM group improved physical activity and overall 
fitness similar to those in the structured group and supports the hypothesis that the new 
LAM recommendation will lead to favorable fitness outcomes in the same manner as the 
old recommendation.  In addition, the LAM treatment was beneficial for decreasing 
percent body fat and blood pressure, variables known to be associated with CVD.  
Additionally, the structured exercise group significantly decreased their fitness level 
during the maintenance period (6 months to 24 months) compared to the LAM group .  
These results indicate LAM may be more effective for long-term behavior change (Dunn 
et al, 1999).   
 Using a similar study design, Schmidt et al (2001) recruited thirty-eight, 
sedentary, overweight (BMI >27 kg/m2) females to participate in a 12 week exercise 
study.  Subjects were divided into one of four groups: control, or 30 minutes of exercise 
that was either continuous, 2 bouts of 15 minutes, or 3 bouts of 10 minutes. The three 
intervention groups were asked to participate in their exercise protocol 3-5 days per week 
at 75% heart rate reserve.  All subjects were instructed to follow a calorie-restricted diet 
of 80% of their resting energy expenditure (measured via metabolic cart). 
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 Results showed that for all groups, there was a significant decrease in calorie 
consumption by 6 weeks that remained constant for the rest of the study.  There were no 
differences in calorie consumption between any of the four groups.  For the three exercise 
groups, there was a significant decrease in body weight, BMI, sum of skinfolds, and waist 
circumference at 12 weeks compared to baseline. In addition, there was a significant 
increase in VO2max in all three exercise groups.  There was no difference between 
groups in any of these measures and there were no significant changes in the control 
group.  This study illustrates that all three exercise protocols resulted in similar 
improvements in health. While the reduction in calories probably contributed to these 
improvements, all groups reduced calories to the same extent. Therefore, the diet effects 
should have been similar across groups and any differences due to exercise regimen 
should have been teased out (Schmidt et al, 2001). 
 Donnelly and colleagues (2000) investigated the difference between an 18 month 
traditional continuous exercise program and an intermittent exercise program.  Twenty-
two overweight (BMI > 25), sedentary women were divided into either a continuous 
(CON) or intermittent (INT) exercise group.  The CON group performed 30 minutes of 
continuous exercise at 60-75% of maximal aerobic capacity, three times per week.  The 
INT group performed two 15 minute bouts of walking at 50-65% HRR, five days per 
week. 
 All measurements were assessed at baseline, 9 months, and 18 months.  Total 
kilocalorie intake did not significantly change during the 18 month period as reported by 
3-day recall. However, the INT group did significantly decrease the amount of calories 
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from fat over the course of the study.  Body weight and percent body fat (measure via 
hydrostatic weighing) decreased significantly across the 18 months of the study in the 
CON group.  The INT group had a significant decrease in these measures at 9 months, 
but returned to baseline by 18 months.  Both groups had a significant increase in maximal 
oxygen consumption after 18 months.  Additionally, both groups had a significant 
increase in HDL cholesterol.  The results of the oral glucose tolerance tests revealed a 
decrease in the area under the curve for insulin in both groups, but only the INT group 
had a decrease in fasting insulin (Donnelly et al, 2000).  This suggests that both groups 
improved their insulin response and/or glucose uptake during a glucose challenge, but 
only the INT group had an improvement in baseline insulin measures.  This could 
indicate an improvement in either β-cell function or an improvement in basal insulin 
sensitivity. 
 Overall there was a 2.1% decrease in body weight in the CON group by 18 
months and a 1% decrease in the INT group at 9 months only.  The INT group returned to 
baseline body weight by 18 months.  The authors acknowledge that the changes in body 
weight for both groups were small and that these small changes are not usually associated 
with improvements in cardiovascular risk factors such as lipids and insulin.  However, 
they found an increase in HDL cholesterol and an improved insulin response to glucose 
load in the INT group irrespective of body weight changes.  Therefore, they conclude that 
these improvements may be contributed to their change in physical activity alone.  In 
addition, improvements in HDL and metabolic parameters were similar between groups 
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suggesting that intermittent exercise is as effective as continuous exercise in improving 
these variables (Donnelly et al, 2000). 
 Further studies have reported similar results.  Jakicic et al (1995), prescribed a 
twenty week intervention, for obese, sedentary females, in which there was a short bout 
group and a long bout group.  Both groups exercised for 20-40 minutes, the short group 
did 10 minute bouts while the long group did one continuous bout, five days per week.  
In addition, both groups participated in a dietary program that reduced total caloric intake 
and fat intake. Results indicated that even though both groups significantly improved 
their predicted VO2max, the short bout group may produce better overall health gains 
since this group’s adherence was better and they reported exercising more days per week 
and the trend for weight loss was greater in this group. 
 DeBusk et al (1990), compared the difference between 30 minutes of continuous 
exercise and three, 10 minute bouts in healthy middle-aged men for 8 weeks. For both 
groups, VO2max increased significantly.  Murphy and Hardman (1998) compared long 
and short bouts of walking in sedentary women. Both groups walked for 30 minutes, 5 
days a week, at 70-80% of their maximum heart rate for 10 weeks.  The long bout 
consisted to one 30 minute walk and the short bout consisted of three, ten minute bouts.  
Again, both groups significantly increased their VO2max.  In addition, Murphy and 
Hardman (1998) found a decrease in the sum of skinfolds in both groups, but only the 
short bout groups saw an improvement in body weight and waist circumference. 
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Summary 
Past research is still controversial as to what extent LAM improves cardiovascular 
fitness, increases physical activity and improve body composition and decreases body 
weight. Additionally, more research is needed to determine if LAM, in comparison to 
structured exercise, will also improve non-traditional cardiovascular risk factors that are 
linked to cardiovascular disease, possibly decreasing the risk of atherosclerosis and the 
development of insulin resistance syndrome and/or type 2 diabetes.  It is clear that PAI-1 
and CRP are nontraditional risk factors that may be useful in examining this. Specifically, 
these studies need to be investigated in populations at risk for cardiovascular disease and 
for which little information has been accumulated, such as African-American women.   
 51
 
 
CHAPTER III 
OUTLINE OF PROCEDURES 
 
 
 
Subjects 
 
Twenty-four apparently healthy, sedentary African-American female volunteers, 22-
53 years of age, with a BMI ≥ 23 kg/m2, were recruited and randomly assigned to one of 
three groups; control, lifestyle-activity modification, or traditional exercise.  Sedentary 
individuals were defined as those not participating in any regular physical activity for at 
least the past 6 months.  Recruitment included placement of flyers on the University of 
North Carolina at Greensboro, North Carolina Agricultural and Technical State 
University, and Bennett College campuses, around the Triad area, and announcements 
made through local women’s organizations.  Exclusion criteria included:    
1. History of myocardial infarction, stroke, or diagnosed diabetes. 
2. Currently engaging in physical activity at least 3 days per week for ≥ 20 minutes 
each time, for at least the past 6 months. 
3. Currently engaging in an organized weight loss program. 
4. Planning to move from the local area during the length of the study. 
5. Pregnant or planning to become pregnant. 
6. Taking medication that could alter exercise performance, appetite or metabolism 
(excluding oral contraceptives).  
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Assessment 
Subjects underwent an orientation session at which time the details and protocol 
for the study were explained and eligibility criteria were assessed.  Eligible subjects 
completed a medical history (see Appendix A) and physical activity readiness (PAR-Q) 
questionnaire (see Appendix B), which were used to determine eligibility.   Informed 
consent forms were signed (see Appendix C). All assessments were completed at pre- and 
post-intervention. 
Metabolic and Inflammatory Markers 
Approximately 60 milliliters of blood was collected into plain and EDTA filled 
vacutainer tubes after an overnight fast of at least 10 hours.  Standard venipuncture 
technique was used to collect blood from the antecubical vein by a certified phlebotomist.  
After collection, the EDTA tube was placed on ice and the other tube was left at room 
temperature for at least 30 minutes.  Both tubes were then centrifuged and serum and 
plasma were drawn off and stored at -80oC until analysis.  
C-reactive protein levels were determined via an Ultra-sensitive ELISA from 
Diagnostic Systems Laboratories, Inc.  PAI-1 was measured by immuno-assay from 
HYPHEN BioMed.  Insulin was determined by ELISA from Mercodia and glucose was 
determined by colorimetric assay from Roche Diagnostics Systems (see Appendix D). 
Serum was used for CRP and EDTA plasma was used for PAI-1, insulin and glucose. 
Intra-assay coefficients for all measurements were less than 10%. 
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Insulin resistance was assessed using the Homeostasis Model Assessment 
(HOMA-IR), which was calculated as insulin (uIU/ml) * glucose (mmol/L) / 22.5 
(Matthews, 1985).   
Anthropometric Measurements 
 Height was measured using a wall-mounted stadiometer and weight using a 
standard physician and hospital balance beam scale.  Body weight and height was 
measured barefoot, to the nearest 0.1 kg  for weight and the nearest 0.1 cm for height.   
BMI was calculated using body weigh and height as follows: weight (kg)/height (m2). 
Waist circumference (cm) was measured three times for reliability and the average was 
taken.  Circumference was measured at the narrowest part of the torso, above the 
umbilicus, using a tension-scale gauged measurement tape (ACSM, 2005).  
Body Composition 
Body composition was assessed via 3-site skinfold (tricep, suprailiac, and thigh) 
using Harpendon skin fold calipers.  Body density was calculated from three-site skinfold 
using the Jackson and Pollock equation and percent body fat was calculated using the Siri 
equation (ACSM, 2005).  Although there are ethnic specific calculations for percent body 
fat, the Jackson and Pollock equation is widely used and has been extensively validated.  
Physical Activity 
 Energy expenditure was measured via Omron pedometer (Model HJ105).  The 
total number of steps was averaged from seven days at both baseline and at 12-weeks 
post-intervention.   
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Cardiorespiratory Fitness 
Subjects completed a sub-maximal cycle ergometer test following the YMCA 
protocol set by the American College of Sports Medicine (ACSM, 2005).  After 
habituation to testing procedures and equipment, subjects were equipped with a heart rate 
monitor and testing began.  The following YMCA sub-maximal procedure was used: 
1. A 2-3 minute warm-up on the cycle ergometer at the workload that was used for 
stage one. 
2. The workload for the first stage of the test was 150 kgm/min (0.5 kg at 50 rpm). 
3. Once steady-state was reached, the heart-rate in the third minute of the stage 
dictated the workload for the next stage in accordance with the ACSM’s 
Guidelines for Exercise Testing and Prescription (2005). 
4. The third and fourth (if required) stages were set according to the same criteria 
used in stage 2. 
5. Upon completion of two consecutive stages that met the criteria for cessation, the 
workload was dropped to the level of the warm up or less for at least a 2-minute 
cool-down stage. 
6. The subject’s heart rate was monitored following exercise and the subject was 
asked to remain in the lab until heart rate reached the individual’s pre-exercise 
level. 
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7. The heart rate measured during the last stage of the exercise protocol was plotted 
against work rate as outlined by the ACSM’s Guidelines for Exercise Testing and 
Prescription (2005). 
 
Exercise Protocols 
 Subjects were randomly assigned to one of three intervention groups for 12 
weeks: control group, lifestyle activity modification (LAM) group, or traditional exercise 
(EXE) group.   
Control Group 
The control group met for risk factor education seminars during weekly one-hour 
meetings for the first six weeks and bi-weekly meetings for the second six weeks.  They 
were instructed not to change their physical activity, which was verified via pedometer 
data.  Subjects in this group were offered free participation in an exercise program upon 
completion of this study. 
Lifestyle Activity Modification 
The participants were instructed to increase levels of low to moderate intensity 
activity in order to accumulate approximately 150 minutes of activity weekly, or 
approximately 30 minutes of accumulated activity on most days of the week.  This group 
also participated in a lifestyle activity curriculum during weekly one-hour meetings for 
the first six weeks and bi-weekly meetings for the second six weeks.  They were educated 
about the incorporation of exercise into activities of daily living. Information was 
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disseminated according to the curriculum recommended by the CDC’s Division of 
Nutrition and Physical Activity in its Guide for Community Action 
(http:/www.cdc.gov/nccdphp/dnpa/physical/index.htm).   
Traditional exercise group 
 The participants were prescribed traditional exercise using exercise equipment of 
the subjects’ choice.  Each subject participated in four low to moderate level (50-65% 
predicted maximum heart rate) group exercise sessions per week (40-60 minutes per 
session) to accommodate the recommendation that individuals accumulate at least 150 
minutes of low-moderate intensity exercise each week.  Each participant was equipped 
with a heart rate monitor to ensure accuracy of exercise level. 
 
Adherence 
 Adherence the control and LAM groups were based on attendance to group 
meetings.  Adherence for the traditional exercise group was based on attendance to 
exercise sessions. In order to be included in analysis, subjects attended at least 75% of 
their prescribed intervention, similar to methods for assessing adherence and attrition 
used in Project Active (Dunn,1997).   
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Data Analysis 
 All analysis was performed using STATISTCA 6 software package. Statistical 
significance was set at p = 0.05.  All measures were checked for normality using Shapiro-
Wilks test.  Transformations were performed on measures with a significant difference in 
normality (p < 0.05).  Transformations were done in the following order until the p-value 
was greater than 0.05: logarithm, inverse logarithm, square root.  Given the small number 
of subjects in the study, normality was checked and transformations were made in order 
to meet the assumption for parametric statistics. Descriptive statistics and baseline group 
differences were checked using a one-way ANOVA.  Repeated measures ANOVA was 
performed to check for a group x time interaction effect.  Tukey HSD was used for all 
post-hoc analysis.   Correlational statistics were run on all data as pre- and post-values 
combined.  Spearman correlations were run on all the delta change data. 
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CHAPTER IV 
RESULTS 
 
 
 
 Twenty-four subjects finished the study.  One subject was eliminated because a  
 
baseline blood sample was not available.  Two subjects were eliminated because baseline 
subject characteristics could not be clarified, leaving twenty-one subjects for data 
analysis. Descriptive statistics are shown in Tables 1 and 2, stratified by group.  Predicted 
VO2max, steps, CRP, PAI-1, insulin and HOMA-IR were significant for normality check 
and transformations were necessary to normalize the data.  Steps, PAI-1, insulin, and 
HOMA-IR required log transformations, predicted VO2max required inverse log and 
CRP required square root transformations.  All tables show original, non-modified data, 
but statistical analyses were performed on the appropriately transformed data.  There 
were no significant differences between groups on any baseline measurements.   
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Table 1: Baseline subject characteristics for each group. Values are mean (SD). 
 
 Ctrl  
N=4 
LAM 
N=9 
Exe 
N=8 
p-value 
Age (years) 40.8 (10.7) 40.1 (9.5) 38.9 (10.7) 0.95 
Weight (kg) 94.1 (15.6) 80.2 (18.5) 80.2 (18.5) 0.58 
Waist (cm) 93.5 (12.4) 87.4 (18.7) 85.4 (14.8) 0.72 
BMI (kg/m2) 34.7 (4.8) 31.5 (8.0) 30.1 (6.4) 0.57 
Predicted VO2max 
(ml/kg/min) 
23.43 (10.74) 20.73 (5.8) 22.94 (6.98) 0.76 
% Body Fat 37.2 (6.3) 33.8 (8.3) 35.2 (8.5) 0.79 
Steps 5457 (4120) 6934 (4651) 5424 (1433) 0.72 
CRP (mg/L) 33.0 (12.7) 22.0 (22.2) 21.6 (21.7) 0.46 
PAI-1 (ng/ml) 24.9 (17.9) 20.1 (24.0) 24.9 (17.4) 0.42 
Insulin (uU/ml) 9.0 (3.8) 9.1 (10.8) 11.0 (4.3) 0.34 
Glucose (mmol/L) 4.8 (1.3) 4.1 (1.2) 5.1 (1.2) 0.24 
HOMA-IR 1.9 (0.8) 1.7 (1.9) 2.5 (1.3) 0.15 
Ctrl  = controls, LAM = lifestyle modification, Exe = traditional exercise 
* average number of steps from seven days 
 
Table 2: Post-intervention subject characteristics for each group. Values are mean 
(SD). 
 
 Ctrl  
N=4 
LAM 
N=9 
Exe 
N=8 
Weight (kg) 94.8 (14.8) 83.1 (25.2) 78.7 (18.4) 
Waist (cm) 98.0 (13.8) 86.0 (19.1) 83.3 (13.3) 
BMI (kg/m2) 35.0 (4.2) 31.3 (8.1) 29.6 (6.1) 
Predicted VO2max 
(ml/kg/min) 
20.28 (8.37) 24.71 (6.52) 29.64 (9.54) 
% Body Fat 38.3 (6.4) 31.6 (9.3) 32.1 (8.2) 
Steps* 7639 (3599) 10431 (2342) 11800 (7390) 
CRP (mg/L) 24.3 (4.2) 21.9 (19.4) 28.8 (17.4) 
PAI-1 (ng/ml) 41.6 (29.1) 14.7 (5.6) 29.1 (22.8) 
Insulin (uU/ml) 10.2 (4.1) 9.9 (9.1) 7.8 (2.7) 
Glucose (mmol/L) 4.5 (1.1) 4.4 (0.8) 4.3 (1.3) 
HOMA-IR 1.9 (0.4) 1.7 (1.3) 1.4 (0.4) 
 
Ctrl  = controls, LAM = lifestyle modification, Exe = traditional exercise 
* average number of steps from seven days 
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 Repeated measures ANOVA showed no overall group effects, however several 
time effects were found (Table 3).  
Table 3: Repeated Measures ANOVA p-values for group, time and group by time 
interaction. 
 
 Group Time Group x Time 
Weight (kg) 0.53 0.33 0.20 
Waist (cm) 0.52 0.54 <0.001 
BMI (kg/m2) 0.51 0.42 0.21 
Predicted VO2max 
(ml/kg/min) 
0.43 0.01 <0.001 
% Body Fat 0.60 <0.001 <0.001 
Steps* 0.42 0.001 0.95 
CRP (mg/L) 0.54 0.83 0.21 
PAI-1 (ng/ml) 0.19 0.10 0.70 
Insulin (uU/l) 0.54 0.97 0.33 
* average number of steps from seven days 
 
The control group had a significant increase in waist circumference with an average of 93 
cm at baseline and 98 cm 12-weeks later (Figure 1).  There was no significant difference 
in waist circumference in the two intervention groups, however there was a trend towards 
a decrease. Although there was no significant change in body weight (Figure 2) or BMI 
(figure 3)in the exercise group, they did have a significant decrease in percent body fat 
(Figure 4).  The average body fat dropped from 35% to 32% (p=0.004).  The control 
group had relatively no change in percent body fat or BMI. 
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Figure 1: Waist circumference at baseline and post-intervention for each group.  
Values are mean (SEM). P-values compare baseline and post-treatment values 
within group. 
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Figure 2: Body weight at baseline and post-intervention for each group.  Values are 
mean (SEM).  
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Figure 3: Body mass index at baseline and post-intervention for each group.  Values 
are mean (SEM).  
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Figure 4: Percent body fat at baseline and post-intervention for each group.  Values 
are mean (SEM). P-values compare baseline and post-treatment values within 
group. 
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 Both the LAM and exercise group had a significant increase in predicted 
VO2max, while the control group had a non-significant decrease (Figure 5).   
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Figure 5: Predicted VO2max at baseline and post-intervention for each group.  
Values are mean (SEM). P-values compare baseline and post-treatment values 
within group. 
 
 
 
In addition, both of these groups had a significant increase in their average number of  
 
daily steps.  The LAM group increased their average steps by 3487 steps and the exercise 
group increased by 6376 steps (Figure 6). 
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Figure 6: Average steps at baseline and post-intervention for each group.  Values 
are mean (SEM). P-values compare baseline and post-treatment values within 
group. 
 
 
 
 Although there were no significant differences in any of the glycemic measures,  
 
there were several notable trends.  The glucose for both the control and LAM groups 
stayed the same, while there was a slight decrease in the exercise group (Figure 7).  The 
control and LAM group had a slight increase in insulin levels, while the exercise group 
had a decrease (Figure 8).  Finally, the control and LAM group had no change in insulin 
resistance measured via HOMA-IR, but the exercise group had a decrease (Figure 9). 
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Figure 7: Glucose at baseline and post-intervention for each group.  Values are 
mean (SEM). 
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Figure 8: Insulin at baseline and post-intervention for each group.  Values are mean 
(SEM). 
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Figure 9: HOMA-IR values at baseline and post-intervention for each group.  
Values are mean (SEM). 
 
 
 
There were no significant changes for PAI-1 or CRP and given the large variation  
 
in these measurements, there were no notable trends (Figure 10 and 11). 
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Figure 10: CRP at baseline and post-intervention for each group.  Values are mean 
(SEM). 
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Figure 11: PAI-1 at baseline and post-intervention for each group.  Values are mean 
(SEM). 
 
 
 
Correlational statistics showed several significant relationships (Table 4).  Both  
 
PAI-1 and CRP were positively correlated with body weight, percent body fat, and BMI 
and PAI-1 was positively correlated with waist circumference. CRP was also negatively 
correlated with predicted VO2max.  Additionally, PAI-1 was positively correlated with 
insulin and HOMA-IR.  Insulin measures were positively correlated with waist 
circumference, BMI and percent body fat. Spearman correlations revealed a positive, 
significant correlation with percent change in body weight, BMI, and percent body fat 
with change in insulin and HOMA-IR.  Additionally, change in body weight was 
positively correlated with change in predicted VO2max. 
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Table 4: Significant correlations for all variables, pre- and post-intervention 
measures combined.  R and p-values shown. 
 
 
Weight 
(kg) 
Waist 
(cm) 
BMI VO2max %BF CRP PAI-1 Insulin Glucose
Waist 
(cm) .8335         
  p<.001         
BMI .9331 .919        
  p<.001 p<.001        
VO2max -.3420 -.3457 -.3737       
  p=.041 p=.039 p=.025       
%BF .7951 .8605 .8465 -.6200      
  p<.001 p<.001 p<.001 p<.001      
CRP .3383  .4081 -.3322 .3465     
  p=.044  p=.013 p=.048 p=.038     
PAI-1 .5856 .4952 .4599  .4087     
  p<.001 p=.002 p=.005  p=.013     
Insulin  .3782 .3393  .3486 .3220 .3671   
   p=.023 p=.043  p=.037 p=.055 p=.028   
HOMA-
IR  .3454 .3294    .3360 .8762 .4034 
   p=.039 p=.050    p=.045 p<.001 p=.015 
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CHAPTER V 
DISCUSSION 
 
 
 
Anthropometric and Body Composition: 
Based on previous research, we anticipated a decrease in anthropometric 
measures and an improvement in body composition. Our results do not show a decrease 
in body weight, BMI, or waist circumference in either intervention group, however, the 
control group did have an increase in waist circumference. Additionally, the exercise 
group had a significant decrease in percent body fat and the LAM group showed a non-
significant decrease.  
Dunn et al (1999) found a similar decrease in percent body fat for both LAM and 
exercise groups after 24 months of intervention and Schmidt et al (2001) reported a 
decrease in body weight, BMI, percent body fat and waist circumference after a twelve 
week intervention consisting of a continuous exercise group, a group that participated in 
two bouts of 15 minutes per day and a third group with three, 10 minute bouts per day, all 
of whom participated in their assigned protocol 3-5 days per week at 75% of their heart 
rate reserve. However, this study also contained a diet component that contributed to their 
improvement in body composition, even though there were no differences in calorie 
intake between groups.  Donnelly et al (2000) saw improvement in anthropometric 
measures and/or body composition in both a continuous and intermittent intervention at 
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nine months in an eighteen month study.  However, the intermittent group returned to 
baseline body weight and percent body composition at eighteen months. 
There were few changes in anthropometric measures in the two intervention 
groups in the current study however, there was a significant increase in waist 
circumference in the control group, which suggests that the increase in activity level 
prevented an increase in waist circumference in the exercise groups. 
The LAM and exercise group both had a significant increase in number of steps 
and both increased their average steps to > 10,000 per day as recommended (Tudor-
Locke and Bassett, 2004). Cross-sectional studies have shown that individual who 
accumulate 10,000 step or more a day have a significantly lower BMI, waist 
circumference, and percent body fat (Krumm et al, 2006, Thompson et al, 2004) and this 
has been shown to be true in a group of African-American females as well (Hornbuckle 
et al, 2005).  In the current study, only the structured exercise group had a significant 
decrease in percent body fat, suggesting the LAM group did not participate in either 
enough activity, the intervention was not long enough to produce significant changes or 
the intensity was not great enough to illicit a change in body composition. Swartz et al 
(2003) conducted a walking study in which participants were instructed to accumulate 
10,000 steps per day and after eight weeks, subjects showed improved glucose tolerance, 
but no changes in body weight or composition were made. These findings suggest that 
perhaps a longer intervention period is necessary to see changes in body composition, 
even when significant alterations in activity level have occurred for short durations. 
  A limitation to this study is that adherence for the LAM group was calculated 
based on attendance to the group meetings and not adherence to a specified amount of 
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activity completed per day (i.e. # of days that 10,000 steps were achieved). Additionally, 
the number of steps were calculated as an average over the course of one week at baseline 
and at 12 weeks.  The number of steps taken each day over the course of the 12 week 
study is not known. 
Cardiovascular Fitness 
 There was a significant increase in predicted VO2max in both activity groups.    
These results are consistent with other findings.  In studies ranging from 8 weeks to 24 
months, for both men and women, VO2max significantly increased with intermittent 
and/or continuous exercise interventions (Dunn et al, 1999, Schmidt et al, 2001, 
Donnelly et al, 2000, Jakicic et al, 1995, DeBusk et al, 1990, Murphy and Hardman, 
1998). Additionally, there was a significant correlation between percent body fat, body 
weight, BMI, waist circumference and predicted VO2max.   
Glycemic Measures 
 There were no significant changes in glucose, insulin or HOMA-IR measures.  
However, there was a tendency for the exercise group to lower their insulin levels and 
reduce their HOMA-IR values. It should be noted that for a study population that 
included overweight or obese women, their glycemic indicators were extremely good.  
Glucose measures were in the normal range (mean 4.6 mmol/L), however insulin levels 
were very low.  There is no set standard for insulin levels, but in general measures from 
6-26 uIU/ml are considered normal (Pagna and Pagna, 2003).  Normal HOMA-IR values 
are reported around 1 and values greater than 4 are considered insulin resistant (Quon et 
al, 2001).  Osei et al (2005) reported average (SD) insulin levels of 13.01 (±9.32) uIU/ml 
in normal glucose tolerant African-Americans.  The average HOMA-IR value for this 
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group was reported at 2.81 (± 2.06).  Additionally, Patel et al (2006) found that mean 
(SD) levels of insulin in African-American females was 13.5 (±9.4) uIU/ml and the mean 
HOMA-IR value was 3.0 (±2.4).  HOMA-IR values for African-American women have 
been reported has high as 15.8, compared to 8.6 in Caucasian women (Lamonte et al, 
2005). 
 The results of this study showed no significant improvements in glycemic 
measures, however, since the subjects baseline characteristics classified them as very 
healthy and extremely insulin sensitive (average insulin = 9.8 (± 7.5) uIU/ml and average 
HOMA-IR = 2.0 (±1.5)), it is possible that no significant improvements could be made. 
 As expected, change in insulin and HOMA-IR measured were correlated with 
changes in body weight, body mass index, and body composition.   
Plasminogen Activator Inhibitor-1 
The current study did not show a change in PAI-1 antigen in any of the groups.  It 
was hypothesized that PAI-1 would decrease, specifically in association with an 
improvement in body composition and an increase in activity level.  Our results included 
a significant increase in number of steps and predicted VO2max in both the LAM and 
exercise group. Given this, the hypothesis that PAI-1 would decrease in conjunction with 
an increase in activity level is rejected.  The exercise group had a significant decrease in 
percent body fat, but no other anthropometric changes.  Therefore, it is likely that the 
change in percent body fat was not strong enough to illicit a change in PAI-1.   
Past research is controversial.  Some studies show a decrease in PAI-1 with a 
decrease in body weight changes, independent of activity level and vice versa.    PAI-1 is 
not only expressed in the liver, but also in adipose tissue (Shimomura et al, 1996) and 
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PAI-1 has been shown to have a dose dependent relationship with a decrease in weight 
loss (Folsom et al, 1993).  Vague et al (1986) found a positive association between BMI 
and PAI-1 levels.  
Individuals that are sedentary tend to have higher levels of both PAI-1 antigen 
and PAI-1 activity (DeSouza et al, 1998). Studies with exercise or lifestyle interventions 
that had concomitant reductions in body composition, consistently report reductions in 
PAI-1 (Folsom et al, 1993, Lindahl et al,1999, Marvi et al 1999). Interestingly, Marvi et 
al (1999) found a decrease BMI, percent body fat and PAI-1 activity and antigen levels 
with only two, ten minute bouts of exercise per day for twelve weeks. However, this 
exercise intervention was done in conjunction with a low-calorie diet.  In support of the 
role of change in body composition for reductions in PAI-1, Bodary et al (2003), found 
no change in PAI-1 activity or antigen with an intense exercise program that resulted in 
no change in body weight. Conversely, only one study (Hayase et al 2003) found a 
decrease in PAI-1 antigen in a 10 week training study that was not correlated with change 
in total fat mass.   
In the current study, the exercise group saw a significant decrease in percent body 
fat, however, there were no other anthropometric improvements seen in either the LAM 
or exercise group.  Both the exercise and LAM group did see a significant improvement 
in activity level (measured via number of steps).  It is possible that the small change in 
body composition and improvement in activity level was not enough to decrease PAI-1.   
Furthermore, decreases in PAI-1 are often associated with decreases in insulin 
measurements and these values did not change significantly in our population.  More 
specifically in African-American females, PAI-1 changes are more strongly related to 
 74
 
changes in insulin resistance (HOMA-IR) than in changes in fat mass (Solano et al, 
2003).   
Studies show that PAI-1 is significantly associated with insulin levels and often 
decrease with a decrease in insulin.  Vague et al (1986) found a positive association 
between insulin levels and Eliasson et al (1994) found that insulin levels are a predictor 
of PAI-1 activity.  Furthermore, PAI-1 is also positively associated with insulin 
resistance, specifically measured via HOMA-IR measures (Lindahl et al, 1996, Vague et 
al, 1986).  This association between insulin and PAI-1 remains even after adjustment for 
age, sex, ethnicity, BMI and glucose tolerance (Festa  et al, 1999).  In addition, Potter can 
Loon et al (1993) showed an association of insulin resistance and PAI-1 via a 
hyperinsulinemic euglycemic clamp.  This specifically shows that peripheral and hepatic 
insulin actions are associated with PAI-1.  The current study did not see any significant 
changes in insulin, glucose, or HOMA-IR measures and there was a significant, positive 
correlation between insulin and PAI-1 levels, as expected.  In addition, this group of 
African-American females was extremely insulin sensitive as measured by their insulin 
levels and HOMA-IR values at baseline.  Solano et al (2003) compared PAI-1 in 
Caucasian (CC) and African-American (AA) women.  Results showed that fasting insulin 
levels and HOMA-IR levels were independently and positively associated with PAI-1 
levels in AA women, but not in CC women.  
 Since there was no change in body weight, BMI, waist circumference or insulin, 
the lack of change in PAI-1 levels is not surprising. Our findings corroborate previous 
studies that indicate that changes in PAI-1 levels are positively correlated with changes in 
anthropometric measures and insulin levels. 
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There was large variability in PAI-1 measures in the current study, with levels 
ranging from 0.32 to 82 ng/ml.  Some subjects showed extreme variability in their pre- 
and post-treatment measurements of PAI-1 and there are many factors that may have 
contributed to this.  PAI-1 fluctuates with circadian rhythm, with the highest measures 
seen in the early morning (Kluft et al, 1988, Juhan-Vague et al, 1992).  It is possible that 
blood was collected at different times for some of these subjects.  One limitation to this 
study was that the time of day for blood collection was not recorded, it can not be 
determined with this subject pool if time of day was correlated with PAI-1 measures.   
 The mean for PAI-1 for all subjects at baseline was 22.9 ng/ml, which is slightly 
higher than the normal range of 10-20 ng/ml (Kluft et al, 1988, Juhan-Vague et al, 1992).  
However, this normal range is affected by body composition. African-American women 
have higher rates of obesity than African-American men and Caucasian men and women 
(Ogden, 2006).  African-American women have significantly higher BMIs than 
Caucasian women (Nelson et al, 2002, Appel et al, 2002, Morrison et al, 2006).  This 
elevated prevalence of overweight and obesity probably contributes to elevated PAI-1 
measures. Solano et al (2003) reported mean (SD) values of PAI-1 antigen at 48.1 (± 32) 
in a group of overweight or obese African-American women.  The average BMI in the 
current study was 32 kg/m2, which explains our higher values of PAI-1. Moreover, 
compared to Solano et al (2003) whose average BMI was 34 kg/m2, our PAI-1 values 
were much lower.  
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C-Reactive Protein 
CRP was also expected to decrease in both treatment groups, under the 
assumption that there would be improvements in body composition and an increase in 
activity level in both groups.  Again, the lack of change in body composition may help 
explain the lack of change in CRP. 
 Most studies show a significant correlation between body composition and CRP 
levels (Hak et al 1999, Tchernof et al 2002, Rawson et al 2003).  Body weight (Tchernof 
et al 2002), waist circumference (Hak et al (1999) and BMI (Rawson et al 2003) have all 
been shown to be independent predictors of CRP levels. Recently, gender differences in 
the association between body weight and CRP were investigated and results indicate that 
this relationship holds only for women (Marcell et al 2005) and that CRP values in 
women were 2-fold greater than in men. 
 Some studies have reported an association between activity level and CRP.  
Maximal oxygen uptake was an independent factor for CRP levels (Kondo et al 2005) 
and higher CRP levels were associated with lower levels of physical activity in a group of 
subjects with type 2 diabetes (MaGavock et al 2004) and elderly patients (Colbert et al, 
2004). However, Colbert et al (2004) reported that the association was lost after adjusting 
for body composition. 
However, some intervention studies show no decrease in CRP with exercise.  
Marcell et al (2005) had subjects participating in either a moderate or intense exercise 
protocol for 16 weeks.  Overall, there were no changes in CRP levels in either group.  
Even when subjects were divided into tertiles based on change in VO2max, there was still 
no change with CRP levels.  Several studies have shown that a decrease in CRP is seen 
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with weight loss alone, without an exercise component, suggesting that any CRP decrease 
seen with an exercise intervention is likely due to the change in body weight and not 
exercise per se (Tchernof et al, 2002, Heilbronn et al, 2001). 
The current study did not see any significant changes in CRP levels. However the 
exercise group did see a non-significant increase whereas the other two groups decreased. 
It has been hypothesized that exercise has an inflammatory component that may actually 
cause CRP levels to increase during an exercise program (Okita et al, 2004, Marcell et al, 
2005).  Additionally, it has been found that acute bouts of aerobic exercise increase 
muscle inflammation and oxidative stress (Bloomer et al, 2005, Pittaluga et al, 2006).  
This may explain the slight increase in CRP seen in the exercise group. As expected, we 
did see a significant, positive correlation with CRP and body weight, BMI and percent 
body fat, which is consistent with previous studies reported above. 
The women’s health study showed that African-American women had a 
significantly higher mean CRP than Caucasian women, however, they also had a 
significantly higher BMI.  When this association was adjusted for BMI, the difference in 
CRP levels dropped from 44.6% to 10.6%, but remained significantly different (Albert et 
al, 2004).  Additionally, Lamonte et al (2005) reported that elevated CRP levels were 
found in 22.7% of African-American women compared to 4.3% of Caucasian women.  
These studies suggest that there may be an independent ethnic factor associated with 
levels of CRP.  However, the median CRP level in the women’s health study was 2.96 
mg/L in the African-Americans, dramatically and significantly lower than found in the 
current study.   
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 Since CRP is an acute phase reactant, which is produced in the liver in response to 
infection, inflammation and trauma, there are many variables that make this protein 
difficult to measure.  CRP levels in these subjects were extremely high.  The normal 
range for CRP is 1-3 mg/L.  CRP levels above 3 mg/L are considered a high risk factor 
for cardiovascular disease (Pearson et al, 2003).  Measurements above 10 mg/L are rarely 
reported in healthy subjects.  In general, elevated levels of CRP are seen with high blood 
pressure, high BMI, smoking, metabolic syndrome and/or diabetes, low HDL, high 
triglycerides, hormone replacement therapy, chronic infection and inflammation (Pearson 
et al, 2003).  Two of our subjects reported taking birth control.  Nearly all of the subjects 
had a high BMI.  Some subjects reported swelling of the legs and/or arms and asthma, 
which could be considered a state of chronic inflammation.  All of these could have 
affected the abnormal CRP values in this study.  
Limitations 
There are several limitations to this study.  The subject size was very small, with 
only four in the control group, nine in the LAM group and eight in the exercise group.  If 
repeated, the subject size should be increased and equally distributed among the groups.  
Although subjects were asked to report all medications that they were taking and any 
current medical conditions the might have, more specific monitoring needs to be done 
given the variables that were used in this study.  It is known that three subjects were 
taking aspirin on a daily basis and one subject was taking Bextra, an anti-inflammatory.  
Both aspirin and anti-inflammatory medications effect the production of CRP (Backes et 
al, 2003).  Generally, these medications reduce inflammation and should reduce CRP 
measures.  However, subjects taking these medications in this study did not have 
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significantly lower CRP values than anyone else.  Two subjects were asthmatic, which is 
a chronic inflammatory condition, thus affecting CRP levels. 
Other possible extraneous variables that may affect PAI-1 and/or CRP were not 
controlled for and include; time of day for blood sampling, non-prescription medications 
such as Vitamin E and C and fish oil supplements that can affect both CRP and PAI-1 
levels. 
 
Future Research and Recommendations 
 The current study had 4 control subjects, 9 LAM subjects, and 8 structured 
exercise subjects.  In order to increase the power of the study and decrease variability, 
more subjects should be included in future research.  The original goal of this study was 
to have 10 in each group.  Although both the LAM and exercise group were close to this, 
the control group had less than half.  This could be due to lack on interest in this group.  
More contact with this group may be beneficial for improving adherence, as well as 
monetary compensation. 
 The current study found no changes in body weight, BMI, insulin, HOMA, CRP, 
and PAI-1.  The above mentioned low subject numbers could have contributed to this.  
However, it is possible that the intervention was not long enough.  Twelve weeks may 
not be long enough to see necessary changes in body weight that may illicit changes in 
insulin, CRP and PAI-1. In addition, the prescribed exercise intensity for the structured 
exercise group may not have been high enough to cause the changes we expected.  The 
intensity was prescribed at 50-65% maximum heart rate.  Several other published studies 
have used higher intensities and a rate closer to 75% may be needed.  Furthermore, diet 
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was not controlled for in this study.  There could have been a kilocalorie change within 
and between the groups that may have affected all the variables measured. 
 Results showed a significant increase in the number of steps in both the LAM and 
exercise group.  The number of steps were calculated and averaged over the course of one 
week at baseline and again at 12 weeks.  This likely does not reflect the true nature of the 
physical activity level of individuals, since it does not reflect the actual steps taken each 
day over the course of the study. In addition, the number of steps for the exercise group 
may be lower since the pedometer does not record activity done on a bicycle or elliptical.  
Furthermore, there was a trend for the control group to increase their number of 
steps.  This could be due to effect of wearing a pedometer and may explain why there 
was no difference between the number of steps in the control group at 12 weeks 
compared to both the LAM and exercise group. Future studies should have the 
participants record their number of steps each day so that both the daily and weekly 
averages can be compared between the two groups throughout the duration of the study.  
This could help tease out differences seen between the LAM and exercise group. 
 One issue that affects PAI-1 levels is the time of day of blood collection.  The 
current study did not record the time of day for blood collection.  Although most blood 
samples were collected in the morning, it is impossible to tell if the times were consistent 
across a given subject. Since PAI-1 levels are known to be highest early in the morning, 
this may alter the findings.  Subjects should be required to come in between a set time 
such as 7:00-10:00 am and the pre- and post-treatment blood collection should be done at 
the same time. 
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 Finally, subjects were required to disclose all medical conditions and medication 
they were currently taken.  In addition to medications, supplements such as vitamins and 
anti-oxidants should be controlled for in future studies.  It is known that such 
supplements can lower CRP levels.  Moreover, subjects taking birth control, aspirin, and 
anti-inflammatories or those with chronic conditions such as asthma, should likely be 
excluded from future studies. 
 
Conclusions 
 In conclusion, twelve weeks of LAM or structured exercise significantly 
improved daily activity level and cardiovascular fitness and prevented an increase in 
waist circumference seen in the control group.  Only structured exercise significantly 
improved body composition. Neither LAM or structured exercise improved 
nontraditional cardiovascular risk factors PAI-1 or CRP. 
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APPENDIX A 
 
MEDICAL QUESTIONNAIRE 
 
The purpose of this questionnaire is to determine if you have any physical limitations that 
may exclude you from participation in this investigation.  All information will be kept 
completely confidential. 
 
A.  Personal Information 
 
Name/Last: _______________ First: ___________ Middle Initial: _______ Date 
of Birth: ___________ Gender: ________ 
Address/Street: ________________________________________________ 
City: _______________  State: ________    Zip Code: ________   
Phone (H): _________________ Phone (w): ________________ 
Phone (cell): ________________ E-mail: ___________________ 
Best way to reach you and when?_____________________________________ 
 
1.  When was your last physical exam? ___________________ 
2.  Please list any serious or chronic illnesses of which you are 
aware.______________________ 
3.  Please list any allergies to medications, foods, or other substances. 
__________________________________________ 
4.  Please list any medication you have been on or presently take 
 Type   Dosage/Frequency  How Long?  Why?  
 
 
 
 
 
________________________________________________________________ 
B.  Medical History 
1.  Illnesses---Please check if you have had any of the following: 
 Illness   Present Past  Dates 
Heart attack 
Anemia 
Asthma 
Epilepsy 
Lung disease 
Stroke 
Gout 
Diabetes 
Hypoglycemia 
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Rheumatic fever 
Heart murmur 
Hernia 
 
2.  Symptoms---During the last 12 months, have you experienced: 
Condition     Yes  No 
High blood pressure 
Swelling of hands and feet 
Pain or cramps in legs 
Orthopedic problems 
Musculoskeletal problems 
ECG abnormalities 
Blurred vision 
Chest pain/pressure 
Shortness of breath 
Unusual fatigue 
Dizziness/light headed 
Significant weight change 
High cholesterol 
Numbness in limbs or face 
 
3.  Is there any chance you are pregnant? 
 
4.  Hospitalizations---List the dates and the reasons for hospitalizations for any 
significant illness. 
  Date  Diagnosis 
1. 
2.  
3.  
 
C.  Family History 
1.  Is your father living? Yes No If not, age at death and cause. 
2.  Is your mother living? Yes No If not, age at death and cause. 
3.  Has you father, mother, grandparents, or siblings had: 
Condition   Yes  No  Who? 
High blood pressure 
Stroke 
Heart attack (<50 yrs) 
Heart attack (>50 yrs) 
Diabetes 
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Cardiovascular disease 
Other 
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APPENDIX B: PHYSICAL ACTIVITES READINESS QUESTIONAIRE 
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APPENDIX C: CONSENT FORM 
 
THE UNIVERSITY OF NORTH CAROLINA 
GREENSBORO 
CONSENT TO ACT AS A HUMAN SUBJECT 
 
 
Project Title:  The Comparison of Lifestyle Activity Modification (LA) and Structured 
Exercise on Obesity-related Risk Factors in African-American Women. 
 
Project Director:  Laurie Wideman, PhD 
 
 
Subject's Name:  
____________________________________________________________________ 
 
Date of Consent:  ____________________________ 
 
 
DESCRIPTION AND EXPLANATION OF PROCEDURES: 
 
The purpose of this study is to compare the effectiveness of two different 
exercise programs on the health status of sedentary African-American women 
between the ages of 18 and 55. 
As a subject, you will be asked to report to the Exercise Physiology 
Laboratory in the Department of Exercise and Sport Science at UNC-Greensboro 
for testing on 3 different occasions.  Prior to participation, you will fill out a 
medical questionnaire and a physical activities readiness questionnaire (PARQ), 
to determine if you have any limitations that may exclude you from the 
investigations.  If you are pregnant, or think you might be, you will be excluded 
from the study.  If you are eligible for the study, you will go through a 
familiarization session.  During the session you will have an opportunity to learn 
how to use the testing bicycle and it will be adjusted to your individual 
dimensions.  At this time you will become accustomed to the use of the oxygen 
consumption equipment.  To measure the amount of oxygen that you consume 
while you exercise, we will use a facemask that covers your nose and mouth and 
has a free flow valve in the front and allows you to easily breathe in and out.  
When you exhale, a small air sample is taken from the valve and analyzed by the 
computer to assess how many calories you are using.  This familiarization visit 
should take about 1 hour. 
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At least 24 hours after your familiarization session, you will return to the lab 
for a sub-maximal cycling test, body composition assessment and blood sample 
collection.  The total amount of time you will be at the Exercise Physiology Lab 
this testing will be approximately 45 minutes (this includes measurements, set-up 
time and data collection).  A certified phlebotomist will draw blood samples, the 
amount of which is comparable to approximately 4 tablespoons.  Prior to the 
exercise test, several measurements will be taken to assess the amount of body fat 
you have.  These measurements will include circumferences of your waist and 
hips and we will measure using a bioelectrical impedance (BIA) device.  You will 
lay flat on a non-conductive table and rest quietly for 5 minutes.  After this time, 
four gel electrodes will be placed on the hand, wrist, ankle and foot of the right 
side of the body.  A very small (5 kHz and 1 MHz) alternating current, that cannot 
be felt, will be applied for approximately 5 minutes.  For the cycling tests, you 
will warm-up for 2-3 minutes at a low intensity, you will then pedal for 6 minutes 
at an increasing intensity, after which you will cool down for 2 minutes, again at a 
low intensity to allow you to recover from your activity.  During the test your 
heart rate will be monitored at all times.  The cycling test will last about 2 
minutes.  You are asked to refrain from drinking alcoholic beverages within 48 
hours of testing and you should abstain from eating and drinking caffeinated 
beverages for the 2 hours prior to testing.  You should also abstain from exercise 
the day of your testing. 
After the testing session, you will be randomly assigned to one of three 
groups: 1) a non-exercise control group; 2) a traditional exercise group; or 3) a 
lifestyle modification group.  The control group will be asked to maintain current 
activity patterns throughout the course of the 12 week study, but will participate 
in 8 meetings at the Corbett Center on the campus of North Carolina A&T State 
University during this time, as well as all testing sessions.  The traditional 
exercise group will meet four times per week at the North Carolina A&T Fitness 
Lab in Moore Gym for cardiovascular exercise sessions using cycling, stair-
stepping or walking on stationary exercise equipment.  Each session will consist 
of a warm up and cool-down period, as well as at least 40 minutes of moderate 
intensity exercise.  We will use heart rate monitors to help you work out at the 
proper intensity.  The lifestyle modification group will meet each week for the 
first 6 weeks of the exercise program and every other week thereafter, for 
educational sessions at the Corbett Center on the campus of A&T.  Participants 
will be instructed to incorporate short bouts of exercise into their normal daily 
routines in order to accumulate at least 30 minutes of moderate activity each day 
for minimum of 5 days per week.  All participants will be asked to continue with 
current dietary patterns throughout the duration of the study.  Activity level will 
be recorded for all groups using daily activity logs, 7-day recall questionnaires 
and occasional use of pedometer and/or heart rate monitors.  After the 12-week 
intervention, you will return to the Exercise Physiology Laboratory at UNC-
Greensboro and repeat the same testing that you did prior to starting the 
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intervention.  The total amount of blood that you will give is approximately equal 
to 8 tablespoons, which is approximately ¼ of the amount you would give for a 
blood donation.  
 
RISKS AND DISCOMFORTS: 
 
 The risks during exercise testing include: fainting, abnormal heart beat, 
abnormal blood pressure response, muscle and joint strains and in rare instances, 
heart attack. The risk of death is less than one in 10,000 tests, which includes 
patients with a history of coronary heart disease. This risk is minimized by 
allowing time for proper warm-up and cool-down, by monitoring heart rate during 
testing, and by using healthy subjects with no known cardiovascular risk factors. 
Personnel will be trained in CPR and the use of the AED (automated external 
defibrillator). There is an AED located in the Exercise Physiology Laboratory. 
Orthopedic injury is also remotely possible, but is not likely since you will be 
instructed on proper treadmill walking technique at your familiarization session. 
 
 Your privacy will be maintained at all times and you will be assigned a 
number when you enter the study. This number will be used on all data and only 
the principal investigator will have a copy of the list of subjects. You will not be 
identified in any way in any publication that results from this study. After 
publication or release of data for destruction, the data from the study will be 
destroyed by shredding.  
 
POTENTIAL BENEFITS: 
 
 Exercise testing will provide you with information regarding your physical 
fitness status. The information gained from this investigation can also be utilized 
to help you design an individualized aerobic program that will be tailored to your 
personal needs. Increases in activity levels have been implicated in the reduction 
of risk associated with obesity, cardiovascular disease, diabetes and other chronic 
health problems. 
 
COMPENSATION/TREATMENT FOR INJURY: 
 
 If any injury occurs during the testing sessions, subjects will be provided with 
on-site first aid and will be advised to seek further medical attention if necessary. 
Neither the institution at which you are being tested [UNC-Greensboro or North 
Carolina A&T State University], the investigators, nor those individuals assisting 
in the administration of the programs will be responsible for any medical care that 
may be required due to an injury resulting from your participation in this 
investigation. 
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CONSENT:  
  
By signing this consent form, you agree that you understand the procedures and 
any risks and benefits involved in your participation in this study. You are free to 
refuse to participate or withdraw your consent to participate at any time without 
penalty or prejudice; your participation is entirely voluntary and any decision you 
make will not effect your participation in future studies. Your privacy will be 
protected because you will not be identified by name as a participant in this study. 
 
The research and this consent form have been approved by the University of 
North Carolina at Greensboro Institutional Review Board and the North Carolina 
A&T State University Institutional Review Board, which insures that research 
involving people follows federal regulations. Questions regarding your rights as a 
participant in this study can be answered by calling Dr. Beverly Maddox-Britt at 
(336) 334-5878. Questions about the research itself will be answered by Dr. 
Laurie Wideman at (336) 334-3234 or Brenda Swearingin at (336) 334-7712. Any 
new information that develops during the study will be provided to you if the 
information might affect your willingness to continue participation in the study. 
 
By signing this form, you are agreeing to participate in the project described to 
you by      
 
___________________________. 
 
 
 
____________________________________ 
Subject's Signature* 
 
 
____________________________________ 
Witness to Signature 
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APPENDIX D: ASSAY PROCEDURES 
 
GLUCOSE ASSAY: 
1. Reconstitute calibrator with 3 ml from 4 ml vial of diluent supplied and gently 
mix for 15 minutes (concentration is 167 mg/dl). 
2. Take 100 µl of calibrator and add to small tubes with 100 µl of diluent to make 
83.5 mg/dl. 
3. Take 100 µl of the 83.5 mg/dl and add to another small tube with 100 µl of 
diluent to make 41.75 mg/dl. 
4. Take 100 µl of 41.75 mg/dl and add to another small tubes with 100 µl of diluent 
to make 20.88 mg/dl. 
5. First set of wells to be filled with 92 µl of distilled water to act as blanks. 
6. Second set to be filled with 2 µl of diluent and 90 µl of distilled water. 
7. Pipette 2 µl of each calibrator and sample into appropriate well and add 90 µl of 
distilled water into each (except as note below) 
a. Seventh set to be filled with 4 µl of 167 mg/dl of calibrator and add 88 µl 
of distilled water. 
b. Eight set to be filled with 8 µl of 167 mg/dl of calibrator and add 84 µl of 
distilled water. 
8. Place on shaker for 20 seconds. 
9. Add 150 µl of glucose reagent to all wells. 
10. Read immediately. 
11. Incubate plate at 37ºC for 3 minutes on plate warmer. 
12. Read plate again. 
 
INSULIN ELISA: 
1. Pipette 25 µl of each calibrator and samples into appropriate wells. 
2. Add 200 µl of enzyme conjugate to each well. 
3. Incubate on plate shaker for 1 hour at room temperature. 
4. Hand wash plate 3 times with wash buffer.  After final wash, invert and tap plate 
firmly against absorbent paper. 
5. Add 200 µl of substrate TMB into each well. 
6. Incubate for 15 minutes at room temperature on plate shaker. 
7. Add 50 µl of stop solution to each well. 
8. Place on plate shaker for 5 seconds and read at optical density at 450 nm. 
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PAI-1 ELISA: 
1. Samples and controls must be diluted five fold with F-sample diluent. 
2. Prepare standards. 
3. Add 100 µl of conjugate to each well. 
4. Add 100 µl of standard and samples to appropriate wells. 
5. Mix gently on plate shaker and incubate for 1 hour at room temperature. 
6. Wash plate 5 times with wash solution. 
7. Add 200 µl of TMB substrate into each well. 
8. Incubate for 5 minutes at room temperature. 
9. Add 50 µl of stop solution (sulfuric acid) into each well. 
10. Wait 10 minutes then read plate at absorbance at 450 nm. 
 
CRP ELISA: 
1. Samples must be diluted 1:100 with standard A. 
2. Add 100 µl of calibrator and samples into appropriate wells. 
3. Incubate for 1 hour on plate shaker at room temperature. 
4. Wash plate 5 times with 250 µl of wash buffer. 
5. Add 100 µl of prediluted peroxidase-labeled CRP antibody. 
6. Incubate for 1 hour on plate shaker at room temperature. 
7. Decant content of plate and wash plate 5 times with 250 µl of wash buffer. 
8. Add 100 µl of TMB substrate solution into all wells. 
9. Incubate 5-10 minutes at room temperature in the dark. 
10. Add 50 µl of stop solution and mix shortly. 
11. Immediately read plate at absorbance at 450 nm.
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APPENDIX E: RAW DATA 
   Subject # group kg1 kg2          
            
            
            
           
           
            
            
            
            
          
            
            
           
         
            
          
       
            
            
            
            
            
           
 
      
          
 
     
          
 
         
waist1 wasit2 bmi1 bmi2
 
vo1 vo2 BF1 BF2 step1 step2
12 Ctrl 73 74 77 79.6 28.6 29.4 15.8 15.4 31.2 34.4 2507 5611
26 Ctrl 110 107.7 104 108 40.3 39.4 18.3 16.1 45.8 47.4 8292 7550
34 Ctrl 99.5 102.3
 
90.8 95.2 35.2 36.2 20.3 16.8 37.7 38 9648 12728
73 Ctrl 94 95 102 109 34.5 35 39.3 32.8 34
 
33.4
 
1381 4666
2 LAM 127 125 127.5 127 46.4 45.9 14.7 15.7 1536 10263
8 LAM 98 100 98.4 97.7 36.5 37.2 18.7 23.6 39.3 39.4 5655 9829
10 LAM 72 72 81.1 79.5 28.8 28.4 18.2 18.7 31.9 29.4 2717 10032
14 LAM 58 59 68 68 23.3 23.8 18.3 28.1 25 25.3 5794 9334
20 LAM 55 54 73 72.4 23.3
 
21.9 18.7 26.7 33 28.5 16182
 
14580
29 LAM 83 83 87 83.2 31 30.9 20.9 23.3 40.2 37.2 5563 7042
40 LAM 80 78 76 70.5 30 29.2 31.8 38.8 24.8 18.3 4953 8086
61 LAM 62 62 75 75.9 24.4 24.4 28.9 25.1 27.8 26.9 12553
 
12866
74 LAM 117 115 100.5 99.8
 
40.2 39.8 16.4 22.4
 
48.4 47.9 7453
 
11846
 9 EXE 60.5 61.4 77.6 78 23.2 23.5 18.2 20 33.6 29.7
13 EXE 90 86.8 99.8 97 40 38.6 20.8 29.6 40.2 38.3 4715
 
11038
 16 EXE 86.4
 
87.7
 
94.5
 
91.4
 
33.3 34.2 20.7
 
22.7 41.4 35.1
18 EXE 73 71 84 85 28.2 27.5 20 23.7 35.9 32.6 3667 9710
49 EXE 57 54 64 60.3 24.2 23.2 25.4 39.4 24.8 22.3 5634 7934
57 EXE 57 84 94.5 89 20.2 29.9 24.6 37.2 36.7 33.3 5049 26242
72 EXE 72 72 66.5 69 23.5 23.5 38.3 44.4 21.6 20 7970 5221
75 EXE 114 113 102 96.8 36.7 36 15.5 20.1 47 45.2 5507 10652
  
  kg1 kg2 waist1 wasit2 bmi1 bmi2 vo1 vo2 BF1 BF2 step1 step2
Mean Ctrl 94.13 94.75 93.45 97.95 34.65 35.00 23.43 20.28 37.18 38.30 5457.00 7638.75 
SEM Ctrl 
 
7.78 7.39 6.21 6.88 2.40 2.08 5.37 4.18 3.17 3.19 2059.89
 
1799.48
 
Mean LAM 83.56 83.11 87.39 86.00 31.54 31.28 20.73 24.71 33.80 31.61 6934.00 10430.89
 SEM LAM 
 
8.58 8.40 6.24 6.36 2.68 2.70 1.92 2.17 2.77 3.11 1550.22
 
780.70
 
MEAN EXE 
 
76.24 
 
78.74 
 
85.36 83.31 
 
28.66 29.55 22.94 29.64 35.15 32.06 5423.67 11799.50
SEM EXE 6.99 6.50 5.22 4.69 2.55 2.17 2.47 3.37 2.99 2.89 506.54 2612.79
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Subject # group
 
CRP1 CRP2 PAI1 PAI2 Ins1 Ins2 Gluc1 Gluc2 HOMA1
 
HOMA2
 12 Ctrl 45.6 24.0 1.907 19.959 5.177 7.274 4.347 5.278 1.000 1.706
26 Ctrl 32.2 27.3 39.555 41.147 6.608 6.666 6.520 5.111 1.915 1.514
34 Ctrl 38.5 27.3 19.687 22.413 13.2 11.316 4.926 4.659 2.890 2.343
73 Ctrl 15.8 18.4 38.544 82.9 11.096 15.491 3.451 2.954 1.702 2.034
2 LAM 54.6 36.9 58.779 21.992 37.401 22.712 3.915 4.649 6.507 4.693
8 LAM 37.4 52.0 14.012 13.814 6.605 8.459 5.111 5.111 1.500 1.921
10 LAM 31.7 23.6 3.109 16.635 1.895 4.873 4.618 4.824 0.389 1.045
14 LAM 52.4 39.8 1.34 2.861 5.54 5.299 2.553 4.524 0.629 1.066
20 LAM 5.5 5.1 7.272 12.042 7.578 5.39 3.571 4.751 1.203 1.138
29 LAM 10.4 6.5 32.561 13.839 8.976 6.271 6.112 4.436 2.438 1.236
40 LAM 0.60 0.04 4.744 12.835 4.368 2.624 4.639 4.916 0.900 0.573
61 LAM 0.6 0.5 0.328 17.915 5.177 5.069 3.900 3.777 0.897 0.851
74 LAM 4.6 32.3 58.8 20.396 4.128 28.424 2.387 2.413 0.438 3.048
9 EXE 2.4 30.3 18.089 21.409 4.691 6.484 6.003 6.581 1.252 1.897
13 EXE 58.4 53.3 12.785 23.119 15.648 8.52 5.988 4.177 4.164 1.582
16 EXE 53.5 37.4 27.371 5.579 15.146 13.419 5.954 3.190 4.008 1.902
18 EXE 9.1 7.0 36.315 20.294 15.266 4.934 6.013 4.447 4.080 0.975
49 EXE 14.6 16.3 5.416 14.168 10.971 5.54 4.835 4.225 2.357 1.040
57 EXE 6.2 14.7 4.806 18.085 8.711 7.361 4.502 3.476 1.743 1.137
72 EXE 14.0 19.5 45.549 62.791 11.504 6.953 2.693 5.522 1.377 1.706
75 EXE 14.5 51.8 49.198 67.12 5.729 9.244 4.669 2.674 1.189 1.099
 
  CRP1 CRP2 PAI1 PAI2 Ins1 Ins2 Gluc1 Gluc2 HOMA1
 
HOMA2
 Mean Ctrl 33.03 24.25 24.92 41.60 9.02 10.19 4.81 4.50 1.88 1.90
SEM Ctrl 
 
6.36 2.10 8.93 14.56 1.88 2.05 0.65 0.53 0.39 0.18
Mean LAM 21.98 21.86 20.11 14.70 9.07 9.90 4.09 4.38 1.66 1.73
SEM LAM 
 
7.40 6.48 8.01 1.87 3.61 3.04 0.40 0.28 0.64 0.44
MEAN EXE 21.58 28.79 24.94 29.07 10.96 7.81 5.08 4.29 2.52 1.42
SEM EXE 7.67 6.15 6.17 8.07 1.52 0.95 0.41 0.45 0.48 0.14
 
